Treatment and prevention of conditions related to respiratory diseases

JP2023549675A5Inactive Publication Date: 2024-11-12UNIV HOUSTON SYST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526000
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-03
Filing Date
2021-11-03
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is an urgent need for safe and long-lasting preventive and therapeutic compositions to combat infectious diseases and various types of cancer, particularly those caused by pathogens such as respiratory viruses and cancer cells, with existing solutions lacking efficacy and safety.

Method used

Compositions comprising lipid-based particles, including antigens and modulators that act as pattern recognition receptor agonists, specifically STING agonists, are developed to elicit immune responses and activate interferon pathways, providing preventive and therapeutic benefits against diseases like respiratory infections and cancer.

Benefits of technology

These compositions effectively stimulate innate and adaptive immune responses, leading to the synthesis and secretion of type I and type III interferons, upregulating IFN-stimulated genes, and providing protection against pathogens and cancer cells, with potential for administration via various routes including intranasal and inhalation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Described herein are compositions and methods for preventing pathogens such as conditions in animals (e.g., subjects).In some cases, the compositions or methods described herein may comprise liposomes that can be used to encapsulate one or more STING agonists.In some cases, the liposomes of the compositions or methods described herein may comprise one or more antigens that are attached to, integrated into, or associated with the liposome membrane of the liposome.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Statements concerning research funded by the federal government

[0001] This invention was made with government support under U01AI148118 granted by the National Institutes of Health. The government has certain rights in this invention.

[0002] Cross-reference of related applications

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 108,980, filed on 3 November 2020. The entire foregoing application is incorporated herein by reference. [Background technology]

[0003]

[0003] There is an urgent need for safe and long-lasting preventive and therapeutic compositions to address various diseases, such as infectious diseases caused by pathogens and various types of cancer. Numerous embodiments of the disclosure of the present invention address the aforementioned needs. [Overview of the Initiative]

[0004]

[0004] In various forms, compositions for use in preventing diseases in animals comprise lipid-based particles comprising an antigen and a modulator, wherein the modulator is a pattern recognition receptor agonist. In various forms, compositions for use in treating diseases in subjects comprise lipid-based particles comprising an antigen and a modulator, wherein the modulator is a pattern recognition receptor agonist. The term “NanoSTING” is used herein to describe various embodiments of the compositions described herein. For example, “NanoSTING” may refer to a composition comprising a modulator (e.g., a pattern recognition receptor agonist, e.g., a STING agonist) and particles (e.g., lipid-based particles, e.g., lipid-based nanoparticles). In some cases, “NanoSTING” refers to a composition comprising a modulator and particles, but without the relevant antigen molecule. In some cases, the term NanoSTING refers to a composition comprising a modulator, a divalent cation (e.g., Mn2+, Mg2+, Ca2+, Zn2+), and particles. In some cases, the term “NanoSTING” is used herein to refer to a composition described herein that includes an antigen molecule, for example, when described in the context of the inclusion of an antigen molecule, and / or the term is used to refer to such a composition when modified to reflect an embodiment that includes an antigen molecule (e.g., “NanoSTING-monomer”, “NanoSTING-trimer”, “NanoSTING-RSV”, “NanoSTING-S”, “NanoSTING-varS”, “NanoSTING-ChimS”, “NanoSTING-N”, “NanoSTING-N10”, or “NanoSTING-N20”). In some cases, the lipid-based particles are liposomes.In some cases, the lipid-based particles contain DPPG (1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)), DPPE (1,2-bis(diphenylphosphino)ethane), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DPPE-PEG2000 (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]), cholesterol, or a combination thereof. In some cases, the lipid-based particles contain DPPC, DPPG, cholesterol, and DPPE-PEG2000. In some cases, the lipid-based particles contain DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a ratio of 10:1:1:1, respectively. In some cases, the antigen is associated with the outer surface of the lipid-based particles. In some cases, the antigen is covalently or noncovalently bound to the outer surface of lipid-based particles. In some cases, at least a portion of the antigen is integrated into the membrane of the lipid-based particles. In some cases, at least a portion of the antigen is encapsulated within the lipid-based particles. In some cases, the antigen elicits an immune response to disease. In some cases, the antigen contains a weakened pathogen or a portion thereof. In some cases, the antigen contains a lethal pathogen or a portion thereof. In some cases, the antigen contains a peptide or protein of the pathogen. In some cases, the antigen contains a spike protein or a portion thereof. In some cases, the antigen contains a nucleocapsid protein or a portion thereof. In some cases, the antigen contains a chimeric protein. In some cases, the antigen is a trimer. In some cases, the antigen contains a weakened or lethal form of tumor cells. In some cases, tumor cells are associated with cancer. In some cases, the antigen contains a peptide or protein associated with cancer cells. In some cases, modulators in a given subject can activate or inhibit stimulants of the interferon gene (STING) pathway. In some cases, modulators are agonists of the STING pathway.In some cases, the modulator is selected from the group consisting of bis-(3',5')-cyclic dimer guanosine monophosphate (c-di-GMP), cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), amidobenzimidazole, derivatives of amidobenzimidazole, nucleotide modulators, plasmid DNA modulators, or combinations thereof. In some cases, the modulator is an antagonist of the STING pathway. In some cases, the disease includes an infection caused by a pathogen. In some cases, the pathogen is a respiratory pathogen. In some cases, the respiratory pathogen is a virus. In some cases, the virus is selected from influenza viruses, parainfluenza viruses, adenoviruses, enteroviruses, coronaviruses, respiratory syncytial viruses, rhinoviruses, DNA viruses, RNA viruses, or combinations thereof. In some cases, the influenza virus is either influenza A virus or influenza B virus. In some cases, the virus is a respiratory syncytial virus. In some cases, the virus is a coronavirus. In some cases, coronavirus is selected from severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome-associated coronavirus (SARSr-CoV), human coronavirus 229E (HCoV-229E), human coronavirus NL63 (HCoV-NL63), human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), Middle East respiratory syndrome-associated coronavirus (MERS-CoV), severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2), variants of SARS-CoV-2, or combinations thereof. In some cases, disease is a respiratory disease. In some cases, disease includes cancer. In some cases, cancer is selected from tracheal cancer, lung cancer, bronchial cancer, epithelial cancer, hematological cancer, breast cancer, melanoma, ovarian cancer, gynecological cancer, leukemia, lymphoma, prostate cancer, bladder cancer, colon cancer, glioma, sarcoma, glioblastoma, or combinations thereof. In some cases, the cancer is lung cancer. In some cases, the composition is in the form of a vaccine.In some cases, the composition is suitable for administration by a mode of administration selected from the group consisting of intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spray-based, aerosol-based, intraocular, oral, intraocular, intratracheal, intranasal, inhalation, or a combination thereof. In some cases, the composition is lyophilized. In some cases, the lyophilized composition is reconstituted in a sterile solution which may contain excipients. In some cases, the composition is formulated as a monotherapy agent in the form of a unit-dose formulation. In some cases, the composition is formulated in the form of a unit-dose formulation for administration in one or more doses. In some cases, the composition contains an adjuvant. In some cases, the composition is suitable for inducing immunity in a subject against a disease. In some cases, the composition elicits an immune response against a disease. In some cases, the composition elicits an innate immune response in a subject against a disease. In some cases, the innate immune response results in the activation of interferon regulators (IRFs). In some cases, the innate immune response results in the activation of nuclear factor-κB (NF-κB). In some cases, the antigen has an amino acid sequence that is at least 90% identical to SEQ ID NO: 1. In some cases, the antigen has an amino acid sequence that is at least 90% identical to SEQ ID NO: 3. In some cases, the innate immune response results in the synthesis and secretion of type I and type III interferons, and the subsequent upregulation of IFN-stimulated genes (ISGs).

[0005]

[0005] In various forms, methods for preventing disease in a subject include administering the compositions described above or herein to the subject. In various forms, methods for treating disease in a subject include administering the compositions described above or herein to the subject. In some cases, the compositions are suitable for inducing immunity in a subject to disease. In some cases, administration of the compositions to a subject elicits an immune response in the subject to disease. In some cases, administration of the compositions elicits an innate immune response in the subject to disease. In some cases, the innate immune response results in the activation of interferon regulators (IRFs) in the subject. In some cases, the innate immune response results in the activation of nuclear factor κB (NF-κB). In some cases, the innate immune response results in the synthesis and secretion of type I and type III interferons, and subsequently upregulation of IFN-stimulating genes (ISGs). In some cases, the innate immune response results in associated adaptive immunity. In some cases, the disease is caused by a pathogen. In some cases, the pathogen is a respiratory pathogen. In some cases, the respiratory pathogen is a virus. In some cases, the virus is selected from severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome-associated coronavirus (SARSr-CoV), human coronavirus 229E (HCoV-229E), human coronavirus NL63 (HCoV-NL63), human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), Middle East respiratory syndrome-associated coronavirus (MERS-CoV), severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2), variants of SARS-CoV-2, or combinations thereof. In some cases, the disease is cancer. In some cases, cancer is selected from tracheal cancer, lung cancer, bronchial cancer, epithelial cancer, blood cancer, breast cancer, melanoma, ovarian cancer, gynecological cancer, leukemia, lymphoma, prostate cancer, bladder cancer, colon cancer, glioma, sarcoma, glioblastoma, or a combination thereof. In some cases, cancer is lung cancer.In some cases, the composition is administered to the subject by intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spray-based, aerosol-based, intraocular, oral, intraocular, intratracheal, intranasal, inhalation, or a combination thereof. In some cases, the composition is administered to the subject by intranasal administration. In some cases, the composition is administered to the subject by inhalation. In some cases, the composition is administered to the subject in a single dose. In some cases, the composition is administered to the subject in at least two doses, with the first and second doses of the at least two doses administered at intervals of at least 4 hours, at least 6 hours, at least 12 hours, at least 24 hours, at least 36 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 14 days, or at least 28 days. In some cases, the composition is administered in combination with one or more adjuvant compositions or treatments. In some cases, one or more adjuvant treatments are selected from immunotherapy, viral therapy, targeted inhibition, radiotherapy, chemotherapy, or a combination thereof. In some cases, the subjects are mammals. In some cases, the subjects are at risk of having respiratory infections or cancer. In some cases, this method is used to prevent disease establishment in the subjects. In some cases, this method is used to prevent disease progression in the subjects. In some cases, this method is used to prevent the transmission of disease to a second subject. In some cases, the antigen has an amino acid sequence that is at least 90% identical to SEQ ID NO: 1. In some cases, the antigen has an amino acid sequence that is at least 90% identical to SEQ ID NO: 3.

[0006]

[0006] Compositions for use in various forms to prevent diseases or conditions in subjects include lipid-based particles containing a modulator, the modulator being an activator of the immune system. Compositions for use in various forms to treat diseases or conditions in subjects include lipid-based particles containing a modulator, the modulator being an activator of the immune system. In some cases, the modulator is a stimulant of the interferon gene (STING) pathway activator. In some cases, the lipid particles contain poly(ethylene glycol)-lipids (PEG-lipids). In some cases, the lipid-based particles include DPPG (1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)), DPPE (1,2-bis(diphenylphosphino)ethane), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DPPEPEG2000 (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol)-2000), cholesterol, or a combination thereof. In some cases, the lipid-based particles include DPPC, DPPG, cholesterol, and DPPE-PEG2000. In some cases, the lipid-based particles include DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a ratio of 10:1:1:1, respectively. In some cases, the composition includes at least 30 μg of modulator. In some cases, the composition contains at least 120 μg of modulator. In some cases, the agonist is encapsulated in lipid nanoparticles. In some cases, the agonist is adsorbed, covalently coupled, electrostatically interacting, or formulated on the surface of lipid particles. In some cases, a divalent cation is additionally encapsulated, adsorbed, covalently coupled, electrostatically interacting, or formulated on the lipid nanoparticles. In some cases, the disease includes an infection caused by a pathogen. In some cases, the pathogen is a respiratory pathogen. In some cases, the respiratory pathogen is a virus.In some cases, the virus is selected from influenza viruses, parainfluenza viruses, adenoviruses, enteroviruses, coronaviruses, respiratory syncytial viruses, rhinoviruses, DNA viruses, RNA viruses, or combinations thereof. In some cases, the influenza virus is influenza A virus or influenza B virus. In some cases, the disease is a respiratory disease. In some cases, the disease includes cancer. In some cases, the composition is suitable for a mode of administration selected from the group consisting of intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spray-based, aerosol-based, intraocular, oral, intraocular, intratracheal, intranasal, inhalation, or combinations thereof. In some cases, the composition is lyophilized. In some cases, the lyophilized preparation is reconstituted in a sterile solution which may contain excipients before use.

[0007]

[0007] In various forms, compositions for use in preventing diseases or conditions in animals include a STING pathway activator, the activator being delivered into the nasal cavity. In some cases, the composition includes at least 30 μg of modulator. In some cases, the composition includes at least 120 μg of modulator. In some cases, the disease is caused by a virus selected from influenza viruses, parainfluenza viruses, adenoviruses, enteroviruses, coronaviruses, respiratory syncytial viruses, rhinoviruses, DNA viruses, RNA viruses, or combinations thereof. In some cases, the influenza virus is influenza A virus or influenza B virus. In some cases, the disease is bacterial. In some cases, the disease includes cancer.

[0008]

[0008] In various forms, the method comprises administering a composition of any embodiment described above or herein to a subject in need, wherein the composition is administered to the subject in a single dose. In various forms, the method comprises administering a composition of any embodiment described above or herein to a subject in need, wherein the composition is administered to the subject in at least two doses, the first and second doses of the at least two doses being administered at intervals of at least 4 hours, at least 6 hours, at least 12 hours, at least 24 hours, at least 36 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 14 days, or at least 28 days. In some cases, the composition is administered to the subject in four doses. In some cases, the second, third, and fourth doses are administered over a period of 12 to 36 hours after the previous dose. In some cases, each dose contains at least 30 μg of STING pathway activator. In some cases, each dose contains at least 120 μg of STING pathway activator. In some cases, the innate immune response results in the synthesis and secretion of type I and type III interferons (IFNs), and subsequent upregulation of IFN-stimulated genes (ISGs). In some cases, the subjects are mammals. In some cases, this method is used to prevent disease establishment or progression in subjects. In some cases, this method is used to prevent disease transmission to other subjects.

[0009]

[0009] A better understanding of the subject matter features and advantages of the present invention can be obtained by referring to the following detailed description which describes exemplary embodiments in which the principles of the present invention are utilized, and the accompanying drawings are as follows. [Brief explanation of the drawing]

[0010] [Figure 1]

[0010] Figure 1 provides a depiction of compositions comprising liposomes, payloads, and antigens for treating or preventing diseases, according to various embodiments of the disclosure of the present invention. [Figure 2]

[0011] Figure 2A illustrates a method of preventing disease in a subject (e.g., an animal, e.g., a mammal) by administering one or more therapeutic compositions of the present invention to the subject before exposure to a pathogen. Figure 2B illustrates a method of treating disease in a subject by administering one or more therapeutic compositions of the present invention after exposure to a pathogen. [Figure 3]

[0012] Figure 3 shows a schematic diagram of the administration of a composition described herein, comprising liposomes, a trimer antigen, and a STING agonist, for treating or preventing a disease, or of a control composition lacking the trimer antigen and STING agonist, according to an embodiment. [Figure 4]

[0013] Figure 4A shows a schematic diagram of a trimer S-protein incorporated into a composition for treating or preventing a disease, according to an embodiment. Figure 4B shows images from a denatured sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel assay performed on the purified trimer S-protein presented in Figure 4A, according to an embodiment. [Figure 5-1]

[0014] Figure 5A shows a timeline of steps for a method for an in vivo study of an animal subject using a composition described herein to treat or prevent a disease in a subject, according to an embodiment.

[0015] Figure 5B shows a timeline of body weight measurements in an in vivo mouse control study using the compositions described herein for treating or preventing disease, according to an embodiment.

[0016] Figure 5C shows a timeline of body weight measurements in an in vivo mouse control study using a composition described herein, comprising liposomes, a trimer antigen, and a STING agonist, compared to a control treatment using a composition without a trimer antigen or STING agonist, according to an embodiment. [Figure 5-2]

[0017] Figures 5D and 5E show the evaluation of the humoral immune response using antigen-based IgG ELISA analysis of sera on day 7 (Figure 5D) and day 15 (Figure 5E) after administration of the compositions described herein comprising liposomes, trimeric antigen, and a STING agonist, relative to control treatment using a composition that does not comprise a trimeric antigen or a STING agonist, according to an embodiment.

[0018] Figure 5F shows the evaluation of the humoral immune response using antigen-based IgG ELISA analysis of bronchoalveolar lavage fluid obtained from mice on day 15 after administration of the compositions described herein comprising liposomes, trimeric antigen, and a STING agonist, relative to control treatment using a composition that does not comprise a trimeric antigen or a STING agonist, according to an embodiment. [Figure 5-3] ​​​​​​​​​Figure 5K shows the quantification of the levels of S-protein specific IgA detected in the sera of animal subjects on day 24 after treatment with the compositions described herein comprising liposomes, trimeric antigen, and a STING agonist, relative to a control treatment using a composition lacking a trimeric antigen or a STING agonist, according to an embodiment.

[0022] Figure 5L shows the quantification of the levels of S-protein specific IgA detected in bronchoalveolar lavage fluids obtained from mice treated with the compositions described herein comprising liposomes, trimeric antigen, and a STING agonist, relative to a control treatment using a composition lacking a trimeric antigen or a STING agonist, according to an embodiment. [Figure 5-6]

[0023] Figure 5M shows the ID50 levels of the antibody responses determined from pseudovirus neutralization assay measurements of sera from mice treated with the compositions described herein comprising liposomes, trimeric antigen, and a STING agonist, according to an embodiment.

[0024] Figure 5N shows the ID50 levels of the antibody responses of alveolar lavage fluids from animal subjects treated with the compositions described herein comprising liposomes, trimeric antigen, and a STING agonist, according to a bronchial embodiment determined from pseudovirus neutralization assay measurements of bronchoalveolar lavage fluid (BALF). [Figure 5-7]

[0025] Figure 5-O shows ELISpot assay data of interferon gamma (IFNγ) levels detected in samples obtained from the spleen after treatment with the compositions described herein comprising liposomes, trimeric antigen, and a STING agonist, according to an embodiment. [Figure 5-8] Figure 5P shows the protein level mapping of the conserved peptide (15mer) used in the ELISpot interferon gamma quantification assay, according to an embodiment. [Figure 6-1]

[0026] Figure 6A shows an experimental method for performing single cell RNA (scRNA) sequencing (scRNA-seq) on samples obtained from nasopharynx associated lymphoid tissue (NALT), according to an embodiment. [Figure 6-2]

[0027] Figures 6B, 6C, and 6D illustrate flow cytometry gating strategies for isolating live cells for use in single-cell RNA sequencing (scRNA-seq) assays, according to embodiments. In some cases, cells are identified using the flow cytometry gate shown in Figure 6B, single cells are identified from a population of cells obtained using the gate shown in Figure 6B by using the gate in Figure 6C, and live single cells are obtained from a population of single cells obtained using the gate shown in Figure 6C by using the gate in Figure 6D. [Figure 7-1]

[0028] Figure 7A shows homogeneous manifold approximation and projection (UMAP) analysis of immune cells in animal nasopharyngeal lymphoid tissue (NALT) treated with a composition described herein comprising an antigen, liposomes, and a STING agonist, according to an embodiment. [Figure 7-2] Figures 7B, 7C, and 7D show violin diagrams of the relative expression of the B cell markers CD19, Ms4a1, and CD79a, respectively, in immune cell populations obtained from animal subjects treated with the compositions described herein, comprising an antigen, liposomes, and a STING agonist, according to the embodiments. [Figure 7-3] Figures 7E, 7F, and 7G show violin diagrams of the relative expression of the T cell markers CD3d, CD3e, and CD3g, respectively, in immune cell populations obtained from animal subjects treated with the compositions described herein, comprising an antigen, liposomes, and a STING agonist, according to embodiments. [Figure 7-4] Figures 7H, 7-I, and 7J show violin diagrams of the relative expression of the NK cell markers GzmB, Ncr1, and Ccl5, respectively, in immune cell populations obtained from animal subjects treated with the compositions described herein, comprising an antigen, liposomes, and a STING agonist, according to the embodiments. [Figure 7-5]Figures 7K, 7L, and 7M show violin diagrams of the relative expression of the myeloid cell markers CD14, S100a9, and IL-1b, respectively, in immune cell populations obtained from animal subjects treated with the compositions described herein, comprising an antigen, liposomes, and a STING agonist, according to embodiments. [Figure 8-1]

[0029] Figure 8A shows the identification of B cell subpopulations based on homogeneous manifold approximation and projection (UMAP) analysis of scRNA-seq assays performed on animal subjects treated with compositions described herein, comprising antigens, liposomes, and STING agonists, according to embodiments.

[0030] Figure 8B shows the quantification of the relative frequencies of B cell subpopulations identified using UMAP analysis of scRNA-seq assays performed on animal subjects treated with the compositions described herein, comprising an antigen, liposomes, and a STING agonist, according to an embodiment. [Figure 8-2]

[0031] Figures 8C, 8D, 8E, 8F, 8G, and 8H show violin diagrams of the relative expression of CD69, CD38, CD83, CXCR4, Zfp36, and Erg1, respectively, in B cell subpopulations obtained from animal subjects treated with the compositions described herein, comprising antigens, liposomes, and STING agonists, according to embodiments. [Figure 8-3]

[0031] Figures 8C, 8D, 8E, 8F, 8G, and 8H show violin diagrams of the relative expression of CD69, CD38, CD83, CXCR4, Zfp36, and Erg1, respectively, in B cell subpopulations obtained from animal subjects treated with the compositions described herein, comprising antigens, liposomes, and STING agonists, according to embodiments. [Figure 9-1]Figures 9A, 9B, 9C, 9D, 9E, 9F, 9G, 9H, 9-I, 9J, 9K, 9L, and 9M show violin diagrams of the relative expression of CD19, Ms4a1, Ighm, Irf4, Pax5, Sec61b, Fosb, Jun, Tram1, Igha, EGR3, Casp3, and Fos, respectively, in B cell subpopulations identified by UMAP analysis using cells obtained from animal subjects treated with compositions described herein comprising antigens, liposomes, and STING agonists, according to embodiments. [Figure 9-2] Figures 9A, 9B, 9C, 9D, 9E, 9F, 9G, 9H, 9-I, 9J, 9K, 9L, and 9M show violin diagrams of the relative expression of CD19, Ms4a1, Ighm, Irf4, Pax5, Sec61b, Fosb, Jun, Tram1, Igha, EGR3, Casp3, and Fos, respectively, in B cell subpopulations identified by UMAP analysis using cells obtained from animal subjects treated with compositions described herein comprising antigens, liposomes, and STING agonists, according to embodiments. [Figure 9-3] Figures 9A, 9B, 9C, 9D, 9E, 9F, 9G, 9H, 9-I, 9J, 9K, 9L, and 9M show violin diagrams of the relative expression of CD19, Ms4a1, Ighm, Irf4, Pax5, Sec61b, Fosb, Jun, Tram1, Igha, EGR3, Casp3, and Fos, respectively, in B cell subpopulations identified by UMAP analysis using cells obtained from animal subjects treated with compositions described herein comprising antigens, liposomes, and STING agonists, according to embodiments. [Figure 9-4]Figures 9A, 9B, 9C, 9D, 9E, 9F, 9G, 9H, 9-I, 9J, 9K, 9L, and 9M show violin diagrams of the relative expression of CD19, Ms4a1, Ighm, Irf4, Pax5, Sec61b, Fosb, Jun, Tram1, Igha, EGR3, Casp3, and Fos, respectively, in B cell subpopulations identified by UMAP analysis using cells obtained from animal subjects treated with compositions described herein comprising antigens, liposomes, and STING agonists, according to embodiments. [Figure 10-1]

[0032] Figure 10A shows the identification of T cell subpopulations based on homogeneous manifold approximation and projection (UMAP) analysis of scRNA-seq assays performed on animal subjects treated with compositions described herein, comprising an antigen, liposomes, and a STING agonist, according to an embodiment.

[0033] Figure 10B shows the quantification of the relative frequencies of T cell subpopulations identified using UMAP analysis of scRNA-seq assays performed on animal subjects treated with compositions described herein, comprising an antigen, liposomes, and a STING agonist, according to an embodiment. [Figure 10-2]

[0034] Figures 10C, 10D, 10E, 10F, 10G, and 10H show violin diagrams of the relative expression of CD69, Il6ra, CD27, Nr4a1, Tcf7, and Lef1, respectively, in T cell subpopulations obtained from animal subjects treated with compositions described herein, comprising antigens, liposomes, and STING agonists, according to embodiments. [Figure 10-3]

[0034] Figures 10C, 10D, 10E, 10F, 10G, and 10H show violin diagrams of the relative expression of CD69, Il6ra, CD27, Nr4a1, Tcf7, and Lef1, respectively, in T cell subpopulations obtained from animal subjects treated with compositions described herein, comprising antigens, liposomes, and STING agonists, according to embodiments. [Figure 11-1]Figures 11A, 11B, 11C, 11D, 11E, 11F, and 11G show violin diagrams of the relative expression of CD4, CD8a, CD28, IL7R, Npm1, Fos, and Jun, respectively, in T cell subpopulations identified using UMAP analysis with cells obtained from animal subjects treated with compositions described herein, comprising antigens, liposomes, and STING agonists, according to embodiments. [Figure 11-2] Figures 11A, 11B, 11C, 11D, 11E, 11F, and 11G show violin diagrams of the relative expression of CD4, CD8a, CD28, IL7R, Npm1, Fos, and Jun, respectively, in T cell subpopulations identified using UMAP analysis with cells obtained from animal subjects treated with compositions described herein, comprising antigens, liposomes, and STING agonists, according to embodiments. [Figure 12A]

[0035] Figure 12A shows an intercellular interaction network constructed using data obtained from scRNA-seq analysis of cells obtained from nasopharyngeal-associated lymphoid tissue of animal subjects treated with the composition described herein, comprising an antigen, liposomes, and a STING agonist, according to an embodiment. [Figure 12B] Figure 12B shows the predicted ligand-receptor interactions between cells of a subpopulation of GC B cells and cells of a subpopulation of Tfh cells in nasopharyngeal lymphoid tissue (NALT) (from left to right: TNFRSF13C to TNFSF13B; ICOSLG to ICOS; BTLA to TNFSF14; CD40 to CD40LG; IL-21 receptor to IL-21; CXCL12 to CXCR4; CD28 to CD86; CD28 to CD80). [Figure 13-1]

[0036] Figure 13A shows a schematic diagram of a monomeric S-protein incorporated into a composition described herein, which may be useful in immunization of animals (e.g., vaccination), according to an embodiment. Figure 13B shows an image of a denatured SDS-PAGE gel used to characterize the monomeric S-protein depicted in Figure 13A, according to an embodiment.

[0037] Figure 13C shows IgG ELISA quantification of humoral immune response in serum obtained from animal subjects on day 15 ("d15") after treatment with a composition described herein, comprising liposomes, monomer antigen, and STING agonist, compared to a control treatment using a composition without monomer antigen or STING agonist according to an embodiment. [Figure 13-2]

[0038] Figure 13D shows the ID50 levels of antibody responses determined from pseudovirus neutralization assay measurements of serum from animal subjects treated with the compositions described herein, comprising liposomes, monomeric antigens, and STING agonists, according to embodiments (the limit of detection (LoD) is indicated by the dotted line; the horizontal line represents the mean of the data points; and the p-values ​​were calculated by computer using Mann-Whitney statistical analysis).

[0039] Figure 13E shows ELISpot assay data for interferon-gamma (IFNγ) levels detected in samples obtained from the spleen or lungs of animal subjects after treatment with a composition described herein, comprising liposomes, monomeric antigen, and STING agonist, according to an embodiment.

[0040] Figure 13F shows that monomer protein-specific IgA was detectable in nasal lavage fluids of two animals treated with the composition described herein, comprising liposomes, monomer antigen, and STING agonist, according to the embodiment (limit of detection (LoD) is indicated by the dotted line; the horizontal line represents the mean of the data points). [Figure 14]

[0041] Figure 14 shows the average body weight of animals treated with the compositions described herein, comprising liposomes, monomeric antigens, and STING antigens, according to embodiments (error bars indicate the mean standard error). [Figure 15]

[0042] Figure 15 shows the quantification of antibody-secreting cells (ASCs) secreting S-protein-specific IgA detected in samples collected from the spleens of animal subjects after treatment with a composition described herein, comprising liposomes, monomer antigen, and STING agonist, compared to a control treatment using a composition without monomer antigen or STING agonist, according to an embodiment (horizontal lines indicate the mean; error bars indicate the mean standard error). [Figure 16]

[0043] Figure 16 shows a schematic diagram of a step in a method, according to an embodiment, for administering to an animal subject a composition described herein, comprising liposomes, a nucleocapsid protein antigen, and a STING agonist, for treating or preventing a disease, or for administering a control composition lacking the nucleocapsid protein antigen and the STING agonist. [Figure 17]

[0044] Figure 17 shows the induction of interferon response coefficient (IRF) response in THP-1 cells isolated from animal subjects at 6, 12, or 24 hours after treatment with a composition described herein comprising liposomes, nucleocapsid proteins, and cGAMP, according to an embodiment. [Figure 18]

[0045] Figure 18 shows a schematic diagram of a SARS-CoV-2 nucleocapsid protein useful in compositions for treating or preventing disease in animal subjects, according to an embodiment. [Figure 19] Figure 19 shows images from a denatured sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel assay performed on the purified SARS-CoV-2 nucleocapsid protein (N-protein) presented in Figure 18, according to an embodiment. [Figure 20]

[0046] Figure 20A shows the fluorescence emission spectra of DNA-bound DiYO-1 in the presence of the nucleocapsid protein shown in Figure 18 at nucleocapsid concentrations of 0 μM, 0.1 μM, and 0.5 μM, according to the embodiment. Figure 20B shows the fluorescence emission spectra of DNA-bound DiYO-1 in the presence of a DNA-binding positive control (branched-chain polyethyleneimine (PEI)) at various molar ratios (R) of PEI nitrogen to DNA phosphate, according to the embodiment. [Figure 21-1]

[0047] Figure 21A shows a timeline of the steps for intranasal treatment or vaccination and sample collection in a mouse according to an embodiment. [Figure 21-2]

[0048] Figure 21B shows IgG ELISA quantification of humoral immune responses in serum obtained from animal subjects at day 27 ("D27") after treatment with the composition described herein, comprising liposomes, 10 μg of nucleocapsid protein (N-protein) antigen, and STING agonist ("NanoSTING-N10"), compared to treatment with the composition described herein, comprising liposomes, 20 μg of nucleocapsid protein (N-protein) antigen, and STING agonist ("NanoSTING-N20"), and also compared to a control treatment using a composition without nucleocapsid protein antigen or STING agonist ("Control"). Figure 21C shows IgG ELISA quantification of humoral immune responses in bronchoalveolar lavage fluid (BALF) obtained from animal subjects at day 27 ("D27") after treatment with the composition described herein, comprising liposomes, 20 μg of nucleocapsid protein (N-protein) antigen, and STING agonist ("NanoSTING-N20"), and a control treatment using a composition without nucleocapsid protein antigen or STING agonist ("control"). Figure 21D shows IgA ELISA quantification of humoral immune response in serum obtained from animal subjects on day 27 ("D27") after treatment with a composition described herein, comprising liposomes, 10 μg of nucleocapsid protein (N-protein) antigen, and a STING agonist ("NanoSTING-N10"), compared to treatment with a composition described herein, comprising liposomes, 20 μg of nucleocapsid protein (N-protein) antigen, and a STING agonist ("NanoSTING-N20"), and a control treatment using a composition without nucleocapsid protein antigen or STING agonist.The bars and columns in Figures 21B, 21C, and 21D represent the median, and significance was assumed to be *p<0.05;**p<0.01 using the Mann-Whitney test. [Figure 22]

[0049] Figure 22 shows the quantification of ELISpot analysis of interferon-gamma (IFNγ) and interleukin-4 (IL4) in cells obtained from spleen and lung samples after treatment with the composition described herein, comprising liposomes, 20 μg of nucleocapsid protein (N-protein) antigen, and STING agonist ("NanoSTING-N20"), compared to treatment with a control treatment using a composition without nucleocapsid protein antigen or STING agonist. Bars and columns represent medians, and significance was assumed to be *p<0.05;**p<0.01 using the Mann-Whitney test. [Figure 23]

[0050] Figure 23 illustrates a flow cytometry gating strategy for quantifying additional marker expression in CD8-positive cells obtained from animal subjects after treatment with a composition described herein comprising liposomes, nucleocapsid protein (N-protein) antigen, and STING agonist, according to an embodiment. [Figure 24]

[0051] Figure 24A shows flow cytometry quantification of CD137 expression in splenocytes that are also CD8-positive (CD8+) from animal subjects treated with a composition described herein, comprising liposomes, 10 μg of nucleocapsid protein (N-protein) antigen, and a STING agonist ("NanoSTING-N10"), compared to treatment with a composition described herein, comprising liposomes, 20 μg of nucleocapsid protein (N-protein) antigen, and a STING agonist ("NanoSTING-N20"), and also compared to a control treatment using a composition without nucleocapsid protein antigen or STING agonist. Bars and columns represent medians, and significance was assumed to be p<0.05 using the Mann-Whitney test. Figure 24B shows flow cytometry data of CD137 expression in CD8-positive splenocytes obtained from animal subjects after treatment with a control composition described herein that contains liposomes and lacks the nucleocapsid protein antigen and STING agonist, according to an embodiment. Figure 24C shows flow cytometry data of CD137 expression in CD8-positive splenocytes obtained from animal subjects after treatment with a composition described herein that contains liposomes, 10 μg of nucleocapsid protein (N-protein) antigen, and STING agonist ("NanoSTING-N10"), according to an embodiment. Figure 24D shows flow cytometry data of CD137 expression in CD8-positive splenocytes obtained from animal subjects after treatment with the composition described herein, comprising liposomes, 20 μg of nucleocapsid protein (N-protein) antigen, and STING agonist ("NanoSTING-N20"), compared to a control treatment using a composition without nucleocapsid protein antigen or STING agonist, according to an embodiment. [Figure 25]

[0052] Figure 25A shows flow cytometry quantification of granzyme B (GrB) expression in CD8-positive (CD8+) splenocytes from animal subjects treated with a composition described herein, comprising liposomes, 10 μg of nucleocapsid protein (N-protein) antigen, and a STING agonist ("NanoSTING-N10"), compared to treatment with a composition described herein, comprising liposomes, 20 μg of nucleocapsid protein (N-protein) antigen, and a STING agonist ("NanoSTING-N20"), and also compared to a control treatment using a composition without nucleocapsid protein antigen or STING agonist. Bars and columns represent medians, and significance was assumed at *p<0.05 using the Mann-Whitney test. Figure 25B shows flow cytometry data of granzyme B expression in CD8-positive splenocytes obtained from animal subjects after treatment with a control composition described herein that contains liposomes and lacks nucleocapsid protein antigen and STING agonist, according to an embodiment. Figure 25C shows flow cytometry data of granzyme B expression in CD8-positive splenocytes obtained from animal subjects after treatment with a composition described herein that contains liposomes, 10 μg of nucleocapsid protein (N-protein) antigen, and STING agonist ("NanoSTING-N10"), according to an embodiment. Figure 25D shows flow cytometry data of granzyme B expression in CD8-positive splenocytes obtained from animal subjects after treatment with the composition described herein, comprising liposomes, 20 μg of nucleocapsid protein (N-protein) antigen, and STING agonist ("NanoSTING-N20"), compared to a control treatment using a composition without nucleocapsid protein antigen or STING agonist, according to an embodiment. [Figure 26]

[0053] Figure 26A shows flow cytometry quantification of granzyme B (GrB) expression in CD8-positive (CD8+) lung T cells from animal subjects treated with a composition described herein, comprising liposomes, 10 μg of nucleocapsid protein (N-protein) antigen, and a STING agonist ("NanoSTING-N10"), compared to treatment with a composition described herein, comprising liposomes, 20 μg of nucleocapsid protein (N-protein) antigen, and a STING agonist ("NanoSTING-N20"), and to a control treatment using a composition without nucleocapsid protein antigen or STING agonist. Figure 26B shows flow cytometry quantification of CD137 expression in CD8-positive (CD8+) lung T cells from animal subjects treated with a composition described herein, comprising liposomes, 10 μg of nucleocapsid protein (N-protein) antigen, and a STING agonist ("NanoSTING-N10"), compared to treatment with a composition described herein, comprising liposomes, 20 μg of nucleocapsid protein (N-protein) antigen, and a STING agonist ("NanoSTING-N20"), and to a control treatment using a composition without nucleocapsid protein antigen or STING agonist. Figure 26C shows flow cytometry quantification of CD103 expression in CD8-positive (CD8+) lung T cells from animal subjects treated with a composition described herein, comprising liposomes, 10 μg of nucleocapsid protein (N-protein) antigen, and a STING agonist ("NanoSTING-N10"), compared to treatment with a composition described herein, comprising liposomes, 20 μg of nucleocapsid protein (N-protein) antigen, and a STING agonist ("NanoSTING-N20"), and to a control treatment using a composition without nucleocapsid protein antigen or STING agonist.Figure 26D shows flow cytometry quantification of CD8-positive (CD8+) lung T cells expressing both CD69 and CD103 from animal subjects treated with the composition described herein, comprising liposomes, 10 μg of nucleocapsid protein (N-protein) antigen, and STING agonist ("NanoSTING-N10"), compared to treatment with the composition described herein, comprising liposomes, 20 μg of nucleocapsid protein (N-protein) antigen, and STING agonist ("NanoSTING-N20"), and to a control treatment using a composition without nucleocapsid protein antigen or STING agonist. [Figure 27]

[0054] Figure 27 shows the quantification of the interferon response coefficient (IRF) response in THP-1 dual (dua) cells in response to the type I interferon inducer poly(dA:dT) complexed with the cationic lipid-based transfection reagent LyoVec® (InvivoGen) ("poly(dA:dT) / LV") at 6, 12, and 24 hours after exposure to poly(dA:dT) / LV, according to an embodiment. Bars represent relative luminescence (RLU). [Figure 28]

[0055] Figure 28 shows the measurement of body weight of animals subjected to intranasal administration of NanoSTING-N10 and NanoSTING-N20 compositions according to the embodiment. [Figure 29]

[0056] Figure 29 shows quantification of humoral immune responses in serum obtained from animal subjects at day 7 ("d7"), day 14 ("d14"), day 21 ("d21"), and day 27 ("d27") after treatment with the composition described herein comprising liposomes, 10 μg of nucleocapsid protein (N-protein) antigen, and STING agonist ("NanoSTING-N10"), as well as after treatment with the composition described herein comprising liposomes, 20 μg of nucleocapsid protein (N-protein) antigen, and STING agonist ("NanoSTING-N20"), according to embodiments of nucleocapsid protein-reactive IgG ELISA. [Figure 30]

[0057] Figure 30A shows ELISA quantification of IgG reactivity to the receptor-binding domain of alpha ("α"), beta ("β"), and gamma ("γ") variants of the chimeric spike protein trimer, or alpha or gamma variants, using serum samples obtained from animal subjects 28 days after treatment with the composition described herein, which includes liposomes, chimeric spike protein trimer antigen, and STING agonist ("NanoSTING-ChimS"), compared to treatment with the control composition described herein, which includes liposomes and lacks the chimeric spike protein trimer antigen and STING agonist, according to an embodiment. Figure 30B shows ELISA quantification of IgA reactivity to alpha variants of chimeric spike protein trimers using serum samples obtained 28 days after treatment with the composition described herein, which includes liposomes, chimeric spike protein trimer antigen, and STING agonist ("NanoSTING-ChimS"), compared to treatment with the control composition described herein, which includes liposomes and lacks chimeric spike protein trimer antigen and STING agonist, according to an embodiment. [Figure 31]

[0058] Figure 31A shows the interferon-gamma (IFNγ) response quantified using the ELISpot assay in lung samples from animal subjects treated with the NanoSTING-ChimS composition, which contains different spike protein (S-protein) variants from the peptide pool and represents the entire S-protein-derived peptide pool, compared to treatment with the control composition described herein, which contains liposomes and lacks the chimeric spike protein, according to an embodiment. Figure 31B shows the interferon-gamma (IFNγ) response quantified using the ELISpot assay in lung samples from animal subjects treated with the composition described herein, which contains NanoSTING-ChimS liposomes, a gamma variant chimeric spike protein trimer antigen, and a STING agonist, compared to treatment with the control composition described herein, which contains liposomes and lacks the chimeric spike protein, according to an embodiment. Bars and columns represent medians, and significance was assumed to be *p<0.05; **p<0.01 using the Mann-Whitney test. [Figure 32]

[0059] Figures 32A and 32B show the reactivity of IgG to B1 strain respiratory syncytial virus F protein (RSV-F) in ELISA assays performed using serum obtained from animal subjects on days 7 and 14, respectively, after treatment with a composition described herein comprising liposomes, an RSV-F derived antigen, and a STING agonist ("NanoSTING-RSV"), compared to treatment with a control composition described herein containing liposomes and lacking a chimeric spike protein, according to an embodiment. [Figure 33-1]

[0060] Figures 33A, 33B, and 33C show the distribution of liposome particle sizes measured by dynamic light scattering (DLS) according to the embodiment. [Figure 33-2]

[0061] Figures 33D, 33E, and 33F show the zeta potentials of liposomes measured by electrophoretic light scattering (ELS) according to the embodiment. [Figure 34-1]

[0062] Figures 34A and 34C show the distribution of liposome particle sizes measured by dynamic light scattering (DLS) after composition storage at 4°C according to the embodiment.

[0063] Figures 34B and 34D show the zeta potentials of liposomes measured by electrophoretic light scattering (ELS) after composition storage at 4°C according to the embodiment. [Figure 34-2]

[0062] Figures 34A and 34C show the distribution of liposome particle size measured by dynamic light scattering (DLS) after storage of the composition at 4°C according to the embodiment.

[0063] Figures 34B and 34D show the zeta potential of liposomes measured by electrophoretic light scattering (ELS) after storage of the composition at 4°C according to the embodiment. [Figure 35]

[0064] Figures 35A and 35B show the distribution of liposome particle sizes measured by dynamic light scattering (DLS) according to an embodiment, in which case the antigen is stored in solution (Figure 35A) or in lyophilized solid form (Figure 35B). [Figure 36]

[0065] Figure 36A shows the ultraviolet-visible absorption spectrum of a cGAMP (STING agonist) composition according to an embodiment.

[0066] Figure 36B shows a standard curve used in the calculation of the concentration of free STING agonist according to the embodiment. [Figure 37-1]

[0067] Figure 37A shows the time course related to the prevention of the effects of infectious diseases according to the embodiment.

[0068] Figure 37B shows the changes in the animals' body weight over the time period shown in Figure 37A. [Figure 37-2]

[0069] Figures 37C and 37D show that, in one embodiment, pretreatment with a composition containing lipid-based nanoparticles containing 30 μg or 120 μg of STING agonist significantly reduces viral infection in lung and nasal tissues (respectively). [Figure 38]

[0070] Figure 38A shows the time course of the effects of treatment on animals previously exposed to an infectious disease, according to the embodiment.

[0071] Figure 38B shows the changes in the body temperature of the animals over time during the experiment shown in Figure 38A.

[0072] Figure 38C shows the change in the animal's body weight over time during the experiment shown in Figure 38A. [Figure 39]

[0073] Figure 39A shows activation of the interferon-stimulated gene pathway in THP-1 cells incubated with a composition containing 2.5 μg, 5 μg, or 10 μg of lipid-based nanoparticles and a STING agonist, according to an embodiment. Figure 39B shows luminescence in THP-1 cells incubated with a positive control luciferase vector, according to an embodiment. [Figure 40]

[0074] Figure 40 illustrates some of the biological reactions that may be induced by treatments in various embodiments of the compositions and methods disclosed herein. [Modes for carrying out the invention]

[0011]

[0075] Compositions and methods for the prevention (prevention) and / or treatment (treatment) of diseases or pathological conditions, such as respiratory diseases or cancer, in subjects (e.g., animals, e.g., mammals) are disclosed herein. In some cases, preventing a disease or pathological condition includes preventing the establishment of a disease or pathological condition in a subject. In some cases, preventing a disease or pathological condition includes preventing the establishment of a disease or pathological condition in a subject (e.g., after exposure of the subject to a pathogen). In some cases, preventing a disease or pathological condition includes preventing the onset (e.g., progression) of a disease or pathological condition in a subject (e.g., from a first condition to a second, more severe, or advanced condition) (e.g., after establishment of a disease in a subject via infection from a pathogen). In some cases, preventing a disease or pathological condition includes preventing the transmission of a disease or pathological condition from a first subject to a second subject. A composition 10 useful for preventing or treating a target disease or pathological condition may comprise a particle 12, a modulator 16, and / or an antigen 14 (for example, as shown in Figure 1). For example, the compositions described herein may comprise a lipid-based liposome particle, a modulator (e.g., a pattern recognition receptor agonist, e.g., a STING agonist), and an application-specific antigen (e.g., coronavirus spike protein ("S-protein"), a nucleocapsid protein ("N-protein") associated with the liposome particle, or a chimeric antigen protein). In some cases, the association of the application-specific antigen with the liposome particle (e.g., its outer surface) encapsulating the modulator payload can significantly increase the targeting and / or delivery of the modulator payload to the target tissue of interest (e.g., the nasal and / or lung compartments of interest).In some cases, the association of an application-specific antigen with liposome particles (e.g., direct association, association via incorporation into the liposome membrane, or association via coupling to the liposome membrane surface) can increase the efficacy of the composition in preventing and / or treating a disease or pathological condition in a subject, for example, by spatially concentrating the antigen and modulator of the composition (e.g., in the target tissue).

[0012] composition

[0076] A composition for preventing (preventing) or treating (treating) a disease or pathological condition in a subject (e.g., a therapeutic composition) may include a delivery medium (e.g., particles). The delivery medium of a composition useful in preventing or treating a disease or pathological condition in a subject may be particles, for example, lipid-based particles. For example, a composition useful in preventing or treating a disease or pathological condition in a subject may include lipid-based particles, for example, liposomes (e.g., having a membrane with an outer surface and an internal space). In some embodiments, the composition includes one or more modulators (e.g., one or more types of modulators). In some cases, the modulators may include small molecules, proteins or fragments thereof, and / or polynucleotides or fragments thereof. In some cases, a modulator (e.g., a STING agonist) or a combination of modulators may be selected for use in the compositions described herein with respect to their ability to induce activation or inhibition of signaling pathways and / or systemic response pathways (e.g., stimulants of the interferon gene (STING) pathway) in a subject. A composition useful in preventing or treating a disease or pathological condition (or its transmission to a second target) in a subject may contain one or more antigens. A composition useful in preventing or treating a disease or pathological condition (or its transmission to a second target) in a subject may contain multiple antigens. In some cases, the antigens of the compositions described herein can elicit an immune response in a subject, which may be useful in preventing or eliminating a disease (e.g., respiratory disease) or pathological condition (e.g., cancer) in the subject. In some embodiments, a composition for preventing or treating a disease or pathological condition in a subject may contain a modulator (e.g., a STING agonist, e.g., cGAMP) encapsulated within a particle (e.g., a liposome), in which case the antigen is associated with the liposome or a portion thereof (e.g., via incorporation into the liposome membrane).

[0013]

[0077] In some embodiments, the compositions described herein can be used in methods for treating or preventing diseases or pathological conditions in subjects (e.g., mammals, e.g., humans). In some cases, the compositions described herein may be administered to a subject before exposure to a pathogen (e.g., a pathogen that causes respiratory disease or cancer) so that, for example, the subject does not contract a disease or condition associated with exposure to the pathogen (e.g., infection by the pathogen) (as illustrated, e.g., in Figure 2A). In some cases, the compositions disclosed herein may be administered in the form of a vaccine. In some cases, the compositions described herein may be administered to a subject after exposure to a pathogen (e.g., a pathogen that causes respiratory disease or cancer), for example, after the subject has contracted a disease or condition associated with exposure to the pathogen, in order to treat (e.g., alleviate, or in some cases cure) a disease or condition associated with exposure to the pathogen (e.g., infection by the pathogen) (as illustrated, e.g., in Figure 2B).

[0014] particle

[0078] The compositions disclosed in the present invention may include a delivery medium, such as particles. The particles may include means for delivering a payload (e.g., a modulator payload) and / or one or more antigens (e.g., antigens associated with a portion of the particle, e.g., a membrane or outer surface). In some cases, the particles may include a membrane or wall. In some cases, the membrane or wall of the particle may define an internal space. In some embodiments, the internal space of the particle may include one or more modulators. In some embodiments, one or more antigens may be associated with the membrane or wall of the particle (e.g., the outer surface of the membrane or wall of the particle). The particles may include lipid-based particles, carbon-based particles, metal-based particles, or combinations thereof.

[0015]

[0079] The particles of the compositions described herein may be lipid-based particles. In some embodiments, the lipid-based particles may be liposomes. The compositions described herein may contain pulmonary surfactant biomimetic particles. The particles of the compositions disclosed herein (e.g., lipid-based particles) may contain multiple molecules, for example, multiple molecules aggregated into a membrane. In some cases, the particles (e.g., lipid-based particles) or a portion thereof may be anionic (e.g., they may contain an anionic membrane or one or more anionic lipids). For example, the particles (e.g., lipid-based particles) may contain anionic lipids (e.g., DPPE, DPPE-PEG2000, DPPC, DPPG) or neutral fats (e.g., cholesterol). In some cases, the particles of the compositions described herein (e.g., NanoSTING compositions containing lipid-based nanoparticles) may not contain cationic lipids. In some cases, the particles (e.g., lipid-based particles) or a portion thereof may be cationic. In some cases, the particles (e.g., lipid-based particles) may be amphoteric. In some cases, the particles (e.g., lipid-based particles) or a portion thereof may have a net zero charge. In some cases, the particles (e.g., lipid-based particles) or a portion thereof may not have an charge. In some cases, the particles (e.g., liposomes) of the compositions described herein may contain dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, 1,2-bis(diphenylphosphino)ethane (DPPE), cholesterol, or a combination thereof. In some cases, the particles (e.g., liposomes) of the compositions described herein may contain poly(ethylene glycol)-lipids (e.g., PEG-lipids).In some embodiments, the particles (e.g., liposomes) of the compositions described herein may contain DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DPPG (1,2-dipalmitoyl-sn-glycero-3-phospho(1'-rac-glycerol)), DPPE-PEG2000 (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]), cholesterol, or a combination thereof. In some embodiments, the particles may contain a combination of DPPC and DPPG in a molar ratio of, for example, about 10:1. In some cases, the particles may contain a combination of DPPC and cholesterol in a molar ratio of, for example, about 10:1. In some cases, the particles may contain a combination of DPPC and DPPE-2000 in a molar ratio of, for example, about 10:1. In some cases, the particles may contain a combination of DPPG and cholesterol in a molar ratio of approximately 1:1. In some cases, the particles may contain a combination of cholesterol and DPPE-PEG2000 in a molar ratio of approximately 1:1. In some cases, the particles may contain a combination of DPPG and DPPE-PEG2000 in a molar ratio of approximately 1:1. In some cases, the particles may contain DPPC, DPPG, cholesterol, and DPPE-PEG2000. In some cases, the particles may consist of DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a molar ratio of 10:1:1:1, respectively. In some cases, the particles may consist of DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a molar ratio of 20:1:1:1, respectively. In some cases, the particles may consist of DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a molar ratio of 5:1:1:1, respectively. In some cases, the particles may consist of DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a molar ratio of 10:2:1:1, respectively.In some cases, the particles may consist of DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a molar ratio of 10:1:2:1, respectively. In some cases, the particles may consist of DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a molar ratio of 10:1:1:2, respectively. In some cases, the particles may consist of DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a molar ratio of 10:2:2:1, respectively. In some cases, the particles may consist of DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a molar ratio of 10:1:2:2, respectively. In some cases, the particles may consist of DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a molar ratio of 10:2:1:2, respectively. In some cases, the molar ratio of particles containing the first molecule (e.g., lipid-based particles) to particles containing the second molecule may be 1:100 to 1:1, 1:50 to 1:2, 1:25 to 1:3, 1:10 to 1:5, 1:50 to 1:1, 1:25 to 1:1, 1:10 to 1:1, 1:5 to 1:1, 1:3 to 1:1, 1:25 to 1:10, 1:50 to 1:25, 1:100 to 1:50, or greater than 1:100. In some cases, the molar ratio of particles containing the first molecule (e.g., lipid-based particles) to particles containing the second molecule of the disclosure of the present invention may be 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:15, 1:20, 1:25, 1:50, 1:100, or any range in between. In some cases, the molar ratio of particles containing the first molecule (e.g., lipid-based particles) may be 1:5. In some cases, the molar ratio of particles containing the first molecule (e.g., lipid-based particles) may be 1:10. In some cases, the molar ratio of particles containing the first molecule (e.g., lipid-based particles) may be 1:20. In some cases, the molar ratio of particles containing the first molecule (e.g., lipid-based particles) may be 1:50. In some cases, the ratio of particles containing the first molecule (e.g., lipid-based particles) may be 1:100.In some cases, particles containing the first molecule of the composition described herein (e.g., lipid-based particles) may be dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, 1,2-bis(diphenylphosphino)ethane (DPPE), cholesterol, or a combination thereof. In some embodiments, particles containing the second molecule of the composition described herein (e.g., lipid-based particles) may be DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DPPG (1,2-dipalmitoyl-sn-glycero-3-phospho(1'-rac-glycerol)), DPPE-PEG2000 (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]), or cholesterol.

[0016]

[0080] The particles of the compositions described herein may be nanoparticles. Maintaining small particle size (e.g., mean hydrodynamic particle size of less than 300 nanometers (nm), less than 200 nm, less than 150 nm, less than 120 nm, less than 115 nm, less than 111 nm, less than 110 nm, less than 105 nm, less than 100 nm, less than 95 nm, less than 90 nm, less than 85 nm, or less than 80 nm) and / or low polydispersity (e.g., polydispersity index of less than 0.25, less than 0.24, less than 0.23, less than 0.22, less than 0.21, or less than 0.20) can improve particle stability and / or delivery efficiency. In some cases, the particles may have an outer diameter of 1 nm to 500 nm, 1 nm to 750 nm, or 1 nm to 1,000 nm.In some cases, the particles are 1nm-10nm, 1nm-15nm, 1nm-20nm, 1nm-30nm, 1nm-50nm, 1nm-75nm, 1nm-100nm, 1nm-150nm, 1nm-200nm, 1nm-250nm, 1nm-300nm, 1nm-400nm, 1nm-500nm, 10nm-15nm, 10nm-20nm, 10nm-30nm, 10nm-50nm, 10nm-75nm, 10nm~100nm, 10nm~150nm, 10nm~200nm, 10nm~250nm, 10nm~300nm, 15nm~20nm, 15nm~30nm, 15nm~50nm, 15nm~75nm , 15nm~100nm, 15nm~150nm, 15nm~200nm, 15nm~250nm, 15nm~300nm, 20nm~30nm, 20nm~50nm, 20nm~75nm, 20nm~100 nm, 20nm~150nm, 20nm~200nm, 20nm~250nm, 20nm~300nm, 30nm~50nm, 30nm~75nm, 30nm~100nm, 30nm~150nm, 30nm~ 200nm, 30nm~250nm, 30nm~300nm, 50nm~75nm, 50nm~100nm, 50nm~150nm, 50nm~200nm, 50nm~250nm, 50nm~300nm, 7 The particles may have an outer diameter of 5nm-100nm, 75nm-150nm, 75nm-200nm, 75nm-250nm, 75nm-300nm, 100nm-150nm, 100nm-200nm, 100nm-250nm, 100nm-300nm, 150nm-200nm, 150nm-250nm, 150nm-300nm, 200nm-250nm, 200nm-300nm, or 250nm-300nm. In some cases, the particles may have an outer diameter of 1nm, 10nm, 15nm, 20nm, 30nm, 50nm, 75nm, 100nm, 150nm, 200nm, 250nm, 300nm, 400nm, or 500nm. In some cases, the particles may have an outer diameter of at least 1 nm, 10 nm, 15 nm, 20 nm, 30 nm, 50 nm, 75 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 400 nm, or 500 nm.In some cases, the particles may have an outer diameter of up to 1 nm, 10 nm, 15 nm, 20 nm, 30 nm, 50 nm, 75 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 400 nm, 500 nm, 750 nm, or 1,000 nm.

[0017]

[0081] The modulators and / or antigens of the Disclosure of the Invention may associate with the particles of the Disclosure of the Invention. For example, in some embodiments, the antigens and STING modulators of the Disclosure of the Invention may be located in different regions of the particles of the Disclosure of the Invention. In some embodiments, the modulators of the Disclosure of the Invention (e.g., STING modulators) may be encapsulated in the particles (e.g., STING modulator 16 encapsulated in particle 12, as illustrated in Figure 1). In some cases, all or part of the antigens of the Disclosure of the Invention may associate with the surface of the particles (e.g., attached to it, adhered to it, adsorbed onto it, electrostatically interacting with it, covalently bonded to it, non-covalently bonded to it, integrated onto it, or formulated on it) (e.g., antigen 14 on the surface of particle 12, as illustrated in Figure 1). In some cases, all or part of the antigens are encapsulated within lipid-based particles. In some embodiments, association of the antigen with the surface of the particles (e.g., adsorption) can increase the stability of the particles and / or increase the delivery efficiency after administration (e.g., to target tissue).

[0018]

[0082] In some cases, one or more antigens of the disclosure of the present invention may be encapsulated within particles of the disclosure of the present invention (e.g., lipid-based). In some cases, one or more modulators of the disclosure of the present invention (e.g., STING modulators) may associate with the outer surface of the particles. In some embodiments, one or more antigens of the disclosure of the present invention may be encapsulated within particles (e.g., lipid-based), while one or more modulators of the disclosure of the present invention (e.g., STING modulators) may associate with the outer surface of the particles. In some cases, one or more antigens of the disclosure of the present invention may associate with the outer surface of particles of this disclosure (e.g., lipid-based). In some cases, one or more modulators of the disclosure of the present invention (e.g., STING modulators) may be encapsulated within particles. In some embodiments, one or more antigens of the disclosure of the present invention may associate with the outer surface of particles of this disclosure (e.g., lipid-based), while one or more modulators of the disclosure of the present invention (e.g., STING modulators) may be encapsulated within particles. In some embodiments, one or more antigens and one or more modulators (e.g., STING modulators) of the disclosure of the present invention may both be encapsulated within particles (e.g., lipid-based). In some embodiments, one or more antigens and one or more modulators (e.g., STING modulators) of the disclosure of the present invention may both be associated with the surface of particles (e.g., lipid-based). In some cases, one or more antigens of the disclosure of the present invention may be integrated into the membrane of particles (e.g., lipid-based). In some cases, one or more modulators (e.g., STING modulators) of the disclosure of the present invention may be integrated into the membrane of particles (e.g., lipid-based).In some cases, one or more antigens of the disclosure of the present invention may be encapsulated within the particles of the disclosure of the present invention (e.g., lipid-based), while one or more modulators (e.g., STING modulators) are integrated into the membrane of the particles of the disclosure of the present invention (e.g., lipid-based). In some cases, one or more antigens of the disclosure of the present invention may associate with the outer surface of the particles (lipid-based), while one or more modulators (e.g., STING modulators) are integrated into the membrane of the particles of the disclosure of the present invention (e.g., lipid-based). In some cases, one or more modulators (e.g., STING modulators) may be encapsulated within the particles of the disclosure of the present invention (e.g., lipid-based), while one or more antigens of the disclosure of the present invention are integrated into the membrane of the particles. In some cases, one or more modulators (e.g., STING modulators) may associate with the outer surface of the particles of the disclosure of the present invention (e.g., lipid-based), while one or more antigens of the disclosure of the present invention are integrated into the membrane of the particles. In some embodiments, the incorporation of both the antigen and modulator (e.g., STING modulator) of the present invention into particles (e.g., lipid-based) can facilitate coordinated delivery to the cytosol.

[0019]

[0083] In some cases, the compositions described herein may contain divalent ions, such as divalent cations. In some cases, the compositions contain divalent cations formulated on which particles described herein (e.g., lipid-based nanoparticles) are encapsulated within a membrane (e.g., membrane surface), adsorbed thereon, covalently coupled thereto, or electrostatically interacting thereto. In some cases, the compositions contain Mn 2+ Mg 2+ Ca 2+ , and Zn 2+The composition may also contain a divalent cation selected from the following. For example, the composition may contain a modulator (e.g., a STING agonist), particles (e.g., lipid-based nanoparticles), and a divalent cation, such as Mn 2+ Mg 2+ Ca 2+ , or Zn 2+ It may include.

[0020] antigen

[0084] A composition useful in preventing or treating respiratory diseases or pathological conditions in a subject may contain an antigen. The antigen (or part thereof) of the disclosure of the present invention may associate with the surface of particles (e.g., lipid-based particles, e.g., liposomes) (e.g., attached to, adhered to, adsorbed onto, electrostatically interacting with, covalently bound to, noncovalently bound to, integrated onto, or formulated on). In some cases, the antigen may be suitable for inducing immunity in a subject to a disease. For example, in some embodiments, one or more antigens in the composition of the disclosure of the present invention may be capable of eliciting an immune response in a subject to a disease.

[0021]

[0085] The antigens of the compositions described herein may include attenuated or lethal forms, or portions thereof, of disease-causing pathogens (e.g., one or more of the pathogens described herein). In some embodiments, the antigen may include peptides or proteins associated with the pathogen, or portions thereof. In some embodiments, the antigen may include surface proteins of the pathogen (e.g., receptor proteins), or portions thereof. In some embodiments, the antigen may be in the form of a polynucleotide, for example, a polynucleotide that can be used to express a second antigen (e.g., a plasmid DNA molecule expressing a second antigen).

[0022]

[0086] The antigens of the compositions described herein may include the spike protein or a portion thereof. In some cases, the antigens of the compositions described herein may include at least one component of the coronavirus spike protein (S-protein). In some cases, the antigens of the compositions described herein may include the monomeric form of the coronavirus spike protein (S-protein). In some cases, the antigens of the compositions described herein may include the polymeric form of the coronavirus spike protein (S-protein).

[0023]

[0087] In some cases, the antigens of the disclosure of the present invention may include monomeric forms of the SARS-CoV-2 spike protein (S), monomeric forms of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (S), multimeric forms of the SARS-CoV-2 spike protein (S), multimeric forms of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (S), dimeric forms of the SARS-CoV-2 spike protein (S), dimeric forms of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (S), trimeric forms of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (S), or combinations thereof. In some cases, the antigens of the composition may include chimeric proteins (e.g., chimeric spike proteins).

[0024]

[0088] In some cases, the antigen may contain monomeric or multimeric forms of the SARS-CoV-2 spike protein (S) containing the D614G mutation, A222V mutation, S477N mutation, D80Y mutation, S98F mutation, or a combination thereof.

[0025]

[0089] In some embodiments, the antigen may be a mixture of SARS-CoV-2 spike proteins containing different mutations. In some embodiments, the antigen may comprise monomeric or multimeric forms of the nucleocapsid protein. For example, the antigen of the disclosure of the present invention may comprise monomeric or multimeric forms of the SARS-CoV-2 nucleocapsid(N) protein. In some embodiments, the antigen may comprise monomeric or multimeric forms of the SARS-CoV-2 nucleocapsid(N) protein containing the A220V mutation.

[0026]

[0090] In some embodiments, the antigen may include influenza virus antigen or a part thereof, influenza A virus antigen or a part thereof, influenza B virus antigen or a part thereof, parainfluenza virus antigen or a part thereof, adenovirus antigen or a part thereof, enterovirus antigen or a part thereof, coronavirus antigen or a part thereof, respiratory syncytial virus (RSV) antigen or a part thereof, rhinovirus antigen or a part thereof, DNA virus antigen or a part thereof, RNA virus antigen or a part thereof, or a combination thereof. In some embodiments, the antigen may include antigens of severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome-associated coronavirus (SARSr-CoV), human coronavirus 229E (HCoV-229E), human coronavirus NL63 (HCoV-NL63), human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), Middle East respiratory syndrome-associated coronavirus (MERS-CoV), severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2), variants of SARS-CoV-2 (e.g., 20A.EU1, or spike variant D614G), or combinations thereof.In some cases, the antigen may include (e.g., coronavirus) alpha variant spike protein monomers, (e.g., coronavirus) alpha variant spike protein trimers, (e.g., coronavirus) beta variant spike protein monomers, (e.g., coronavirus) beta variant spike protein trimers, (e.g., coronavirus) gamma variant spike protein monomers, (e.g., coronavirus) gamma variant spike protein trimers, (e.g., coronavirus) delta variant spike protein monomers, (e.g., coronavirus) delta variant spike protein trimers, the receptor-binding domain (RBD) portion of (e.g., coronavirus) alpha variant spike protein, the RBD portion of (e.g., coronavirus) beta variant spike protein, the RBD portion of (e.g., coronavirus) gamma variant spike protein, and / or the RBD portion of (e.g., coronavirus) delta variant spike protein.

[0027]

[0091] In some cases, the antigen of a composition or method described herein (e.g., an antigen comprising a nucleocapsid (N) protein) may have the amino acid sequence described in SEQ ID NO: 1. In some cases, the antigen of a composition or method described herein (e.g., an antigen comprising a nucleocapsid protein) may have an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 1. In some cases, the antigen (e.g., an antigen comprising a nucleocapsid protein) may be encoded by the nucleotide sequence described in SEQ ID NO: 2. In some cases, the antigen may be encoded by a nucleotide sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, more than 99%, or 100% identical to SEQ ID NO: 2. In some cases, the antigen of a composition or method described herein (e.g., an antigen containing a spike (S) protein) may have the amino acid sequence of SEQ ID NO: 3. In some cases, the antigen of a composition or method described herein (e.g., an antigen containing a spike (S) protein) may have an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 3. In some cases, the antigen (e.g., an antigen containing a spike (S) protein) may be encoded by the nucleotide sequence described in SEQ ID NO: 4. In some cases, the antigen (e.g., an antigen containing a spike (S) protein) may be encoded by a nucleotide sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, greater than 99%, or 100% identical to SEQ ID NO: 4.

[0028]

[0092] In some cases, it may be advantageous for the compositions described herein (for example, compositions used in the manner described herein) to contain both an N-protein and an S-protein. For example, the compositions described herein may contain an N-protein having an amino acid sequence at least 90% identical to SEQ ID NO: 1, and an S-protein having an amino acid sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 3. For example, the compositions described herein may include an N-protein having an amino acid sequence identical to SEQ ID NO: 1 by 100%, and an S-protein having an amino acid sequence identical to SEQ ID NO: 3 by at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100%.

[0029]

[0093] In some cases, it may be beneficial for the compositions described herein to contain equal amounts of N-protein and S-protein. In some cases, the compositions or methods described herein may benefit from adjusting the ratio of N-protein to S-protein so that the composition contains heterogeneous amounts of N-protein and S-protein. For example, the compositions described herein may contain more N-protein than S-protein. In some cases, it may be beneficial for the compositions described herein to contain more S-protein than N-protein. In some cases, the compositions described herein may include a mass ratio of N-protein to S-protein of less than 1:1,000 (e.g., N-protein:S-protein mass ratio), and may include 1:1,000-1:500, 1:500-1:200, 1:200-1:100, 1:100-1:50, 1:50-1:25, 1:25-1:20, 1:20-1:10, 1:10-1:5, 1:5-1:4, 1:4-1:3, 1:3-1:2, and 1 The compositions may include the following mass ratios: 2-2:3, 2:3-3:4, 3:4-4:5, 4:5-1:1, 1:1-5:4, 5:4-4:3, 4:3-3:2, 3:2-2:1, 2:1-3:1, 3:1-4:1, 4:1-5:1, 5:1-10:1, 10:1-20:1, 20:1-25:1, 25:1-50:1, 50:1-100:1, 100:1-200:1, 200:1-500:1, 500:1-1,000:1, or greater than 1,000:1. In some cases, the mass ratio of the spike protein of the composition described herein to the nucleocapsid protein of the composition is 1:2.In some cases, the compositions described herein may include molar ratios of N-protein to S-protein less than 1:1,000 (e.g., N-protein:S-protein molar ratio), such as 1:1,000-1:500, 1:500-1:200, 1:200-1:100, 1:100-1:50, 1:50-1:25, 1:25-1:20, 1:20-1:10, 1:10-1:5, 1:5-1:4, 1:4-1:3, 1:3-1:2, and 1 It may include the following molar ratios: 2-2:3, 2:3-3:4, 3:4-4:5, 4:5-1:1, 1:1-5:4, 5:4-4:3, 4:3-3:2, 3:2-2:1, 2:1-3:1, 3:1-4:1, 4:1-5:1, 5:1-10:1, 10:1-20:1, 20:1-25:1, 25:1-50:1, 50:1-100:1, 100:1-200:1, 200:1-500:1, 500:1-1,000:1, or any of the above molar ratios greater than 1,000:1.

[0030]

[0094] In some cases, the compositions or methods described herein may include an N-protein that associates with the membrane of a nanoparticle (e.g., lipid-based) (e.g., is embedded therein, covalently coupled to it, or non-covalently coupled to it), and an S-protein that does not associate with the membrane of the nanoparticle (e.g., is contained within the nanoparticle or is outside the nanoparticle and is not coupled to it (e.g., in simultaneous treatment)). In some cases, the compositions or methods described herein may include N-proteins associated with the membrane of the nanoparticle (e.g., lipid-based) (e.g., embedded therein, covalently coupled to, or noncovalently coupled to) and S-proteins associated with the membrane of the nanoparticle. In some cases, the compositions or methods described herein may include N-proteins not associated with the membrane of the nanoparticle (e.g., lipid-based) (e.g., contained within the nanoparticle or outside the nanoparticle and not coupled to it (e.g., in simultaneous treatment)) and S-proteins not associated with the membrane of the nanoparticle.

[0031]

[0095] In some embodiments, the antigen may be a mixture of SARS-CoV-2 spike proteins and nucleocapsid proteins. In some embodiments, the antigen may be a mixture of SARS-CoV-2 spike proteins containing different mutations and nucleocapsid proteins.

[0032]

[0096] In some cases, the antigen may be influenza virus antigen or a part thereof, influenza A virus antigen or a part thereof, influenza B virus antigen or a part thereof, parainfluenza virus antigen or a part thereof, adenovirus antigen or a part thereof, enterovirus antigen or a part thereof, coronavirus antigen or a part thereof, respiratory syncytial virus (RSV) antigen or a part thereof, rhinovirus antigen or a part thereof, DNA virus antigen or a part thereof, RNA virus antigen or a part thereof, or a combination thereof.

[0033]

[0097] In some embodiments, the compositions disclosed in the present invention are suitable for inducing immunity in a target against cancer. In some embodiments, the antigens of the compositions disclosed in the present invention are suitable for inducing immunity in a target against cancer. For example, in some embodiments, the antigens of the therapeutic compositions disclosed in the present invention can induce an immune response in a target against cancer (e.g., the cancers described above).

[0034]

[0098] In some embodiments, the antigen of the composition disclosed in the present invention may be an attenuated or lethal form of tumor cells (or a portion thereof) associated with cancer. In some embodiments, the antigen may comprise a cancer-related peptide or protein. In some embodiments, the antigen may comprise a surface protein of cancer cells (e.g., a receptor protein).

[0035]

[0099] In some embodiments, the antigen may include a mutated protein from a cancer cell. In some embodiments, the antigen may be a long synthetic peptide that targets cancer mutations.

[0036]

[0100] The antigens of the compositions disclosed herein may take various forms. For example, in some embodiments, the antigen may be a recombinant peptide or protein, or a peptide epitope recognized by T cells. In some embodiments, the antigens of the compositions disclosed herein may comprise a tandem minigene. In some embodiments, the antigen may be in the form of a nucleotide expressing the antigen (e.g., a plasmid DNA molecule expressing the antigen).

[0037] Modulator

[0101] A composition described herein for preventing (preventing) or treating (treating) a disease in a subject (e.g., including particles, e.g., lipid-based particles, and optionally an antigen) may contain a modulator. The modulator of a composition described herein may be a pattern recognition receptor modulator, e.g., a STING modulator (e.g., a STING pathway modulator). In some cases, the modulator of a composition described herein may be a pattern recognition receptor agonist. In some cases, the modulator of a composition described herein may be a pattern recognition receptor antagonist. The compositions disclosed herein may contain various types of STING modulators. For example, in some embodiments, the STING modulator is an antagonist of the STING pathway. In some embodiments, the STING modulator is an agonist of the STING pathway. In some cases, the modulator of a composition described herein can activate the STING pathway in a subject (e.g., a subject to which the composition is administered). In some cases, the modulator of a composition described herein can inhibit the STING pathway in a subject (e.g., a subject to which the composition is administered).

[0038]

[0102] The STING modulators of the compositions described herein may include bis-(3',5')-cyclic dimer guanosine monophosphate (c-di-GMP), cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), amidobenzimidazole, derivatives of amidobenzimidazole, nucleotide modulators, plasmid DNA modulators, nucleic acid modulators, or combinations thereof.

[0039]

[0103] In some embodiments, the STING modulator may be an antagonist of the STING pathway. In some cases, the STING antagonist may be particularly effective in treating and / or preventing diseases in which disease-causing pathogens (e.g., RNA viruses, e.g., rhinoviruses) utilize the STING pathway to promote viral replication. In some cases, the STING antagonist can be used to inhibit viral replication by reducing viral access to the STING pathway. Examples of STING antagonists in some embodiments, but not limited to, include C-178, H-151, and combinations thereof.

[0040]

[0104] In some cases, the modulators of the compositions described herein may be located within the internal space of the particles of the compositions. For example, the modulators may be encapsulated within the particles of the compositions described herein (e.g., lipid-based particles, e.g., liposomes). In some cases, the modulators of the compositions described herein may associate with the surface of the particles of the compositions (e.g., the outer surface of a membrane). In some cases, modulators that associate with the surface of a particle associate by covalent or non-covalent bonding to the surface of the particle. In some cases, modulators that associate with the surface of a particle associate by integration with the surface of the particle (e.g., a membrane).

[0041]

[0105] In some cases, the nucleic acid sequences of the antigens and modulators of the compositions described herein may be at least 85%, at least 90%, at least 95%, or 100% identical. In some cases, a portion of the nucleic acid sequence of the antigens of the compositions described herein may be at least 85%, at least 90%, at least 95%, or 100% identical to the nucleic acid sequence of the modulators of the compositions. In some cases, an antigen containing a nucleic acid sequence that is at least 85%, at least 90%, at least 95%, or 100% identical to the nucleic acid sequence of the modulators described herein may be encapsulated within particles of the compositions described herein (e.g., lipid-based particles) (for example, in this case, the modulator is also encapsulated within lipid-based particles). In some cases, both the antigens and modulators described herein (e.g., when the antigens and modulators contain at least 85%, at least 90%, at least 95%, or 100% identical nucleic acid sequences) are encapsulated within lipid-based particles described herein. In some cases, a composition comprising an antigen and a modulator containing at least 85%, at least 90%, at least 95%, or 100% identical sequences may be delivered into the nasal cavity.

[0042] How to use

[0106] In additional embodiments, the disclosure of the present invention relates to a method for treating (treating) or preventing (preventing) a disease in a subject by administering a therapeutic composition of the present invention to the subject. In a more specific embodiment illustrated in Figure 2A, the method of the disclosure of the present invention includes the steps of administering a therapeutic composition to a subject (step 20), and thereby treating or preventing a disease in the subject (step 22).

[0043]

[0107] As will be described in more detail herein, the therapeutic compositions and methods disclosed in this invention may have numerous embodiments. For example, the therapeutic compositions disclosed in this invention may contain various types of STING modulators and antigens. Furthermore, the methods disclosed in this invention can be used to administer the therapeutic compositions disclosed in this invention to a number of subjects in order to treat or prevent various diseases in various ways.

[0044] Applications / Uses

[0108] In some cases, the compositions and / or methods described herein may be useful in preventing or treating respiratory diseases or conditions, such as those associated with influenza, coronavirus, syncytial virus of the respiratory system, or rhinovirus. In some cases, the compositions and / or methods described herein may be useful in preventing or treating severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), and / or hypercytokinemia (e.g., cytokine storm). In some cases, the compositions and / or methods described herein may be useful in preventing and / or treating cancer, such as lung cancer.

[0045]

[0109] There is an urgent need for safe and effective vaccines against respiratory diseases and cancer. In some cases, the compositions described herein may include a vaccine or therapeutic treatment (e.g., delivered intranasally) containing liposomes containing agonists of interferon gene (STING) pathway stimulants to enable humoral immunity, T-cell immunity, systemic immunity and / or mucosal immunity.

[0046]

[0110] Innate immunity is the first line of defense against invading pathogens. Unlike adaptive immunity, innate immunity can be customized for each pathogen. It can be generated by pattern recognition receptors (PRRs) on host cells that recognize conserved pathogen-associated molecular patterns (PAMPs) 1. This type of recognition can reliably produce an immediate response that does not require customization.

[0047]

[0111] In the case of RNA viruses, the recognition and activation of virus-specific RNA molecules can lead to the activation of interferon regulators (IRFs) and nuclear factor κB (NF-κB). Together, these transcriptional regulators initiate a broad antiviral program that includes the synthesis and secretion of type I and type III interferons, as well as the subsequent upregulation of IFN-stimulated gene (ISG) activity.

[0048]

[0112] This comprehensive antiviral program can apply strong selective pressure to viral replication. Viruses possess evolved and sophisticated countermeasures to interfere with interferon signaling. The interaction between the interferon-mediated response and viral countermeasures is heterogeneous and may explain the heterogeneity in morbidity and mortality observed in humans.

[0049]

[0113] Type 1 interferon response may be suppressed in pathogen infections (e.g., coronavirus or other respiratory pathogens), and subsequently, the balance with the ISG and NF-κB-mediated pro-inflammatory response may become dysregulated. As a result, patients with progressive disease in pathogen infections (e.g., respiratory pathogen infections) may have low interferon signaling but increased tumor necrosis factor (TNF) and interleukin-6 (IL-6) secretion. In fact, individuals with autoantibodies against interferon that neutralize interferon function may be at high risk of progressive disease progression.

[0050]

[0114] Similarly, individuals with a congenital anomaly of type I IFN immunity may develop life-threatening COVID-19 at a higher rate than those without such an error. In some cases, cell line pretreatment with type I interferon can inhibit viral replication in otherwise susceptible cells. While not bound by theory, these considerations may help explain why a lack of a robust type I IFN response may underlie progressive COVID-19.

[0051]

[0115] The stimulant of the interferon gene (STING) pathway is a PRR that senses circular DNA dinucleotides and activates IRF3 and NF-κB, leading to ISG synthesis. While primarily considered important for bacterial and DNA virus sensing, the role of STING in RNA virus-mediated type I IFN and cytokine production requires further investigation. As described herein, the role of STING in RNA virus-mediated type I IFN and cytokine production may be virus and cell type specific.

[0052]

[0116] The sensing of double-stranded RNAs of viral origin, such as coronaviruses, within the cytoplasm of human cells can be achieved by RIG-I-like receptors, such as retinoic acid-inducible gene 1 (RIG-1) and melanoma differentiation gene 5 (MDA5). In some cases, the downstream sensing pathways of these receptors lead to the activation of two IKK-related kinases, namely TANK-binding kinase 1 (TBK1) and inducible IκB kinase (IKKi). In some cases, these kinases are also involved with the activated STING pathway, suggesting that PRRs have evolved to sense different molecules but may converge in their downstream responses.

[0053]

[0117] Using STING agonists as therapeutic agents allows us to leverage this conserved downstream effector response to promote balanced activation of type I interferon, even in the context of SARS-CoV-2 infection. Enabling the release of type I interferon using STING agonists independently of the RIG-1-like receptor increases the likelihood that this will not be exploited by countermeasures evolved by the virus.

[0054]

[0118] Interferon release allows for broad antiviral programs that limit viral replication, potentially reducing disease severity. On the other hand, RNA virus-like rhinoviruses can, in some cases, hijack the STING pathway and promote viral replication. In this situation, inhibiting viral replication by using STING antagonists to diminish the momentum of inflammation may be useful.

[0055]

[0119] While not bound by theory, the therapeutic compositions disclosed in this invention can be used to treat or prevent diseases through various mechanisms of action. For example, in some embodiments, the therapeutic compositions disclosed in this invention can be used to treat a disease in a subject. In some embodiments, the therapeutic compositions disclosed in this invention can be used to prevent a disease in a subject. In some embodiments, the therapeutic compositions disclosed in this invention can be used to treat and prevent a disease in a subject. In some embodiments, the therapeutic compositions disclosed in this invention can be used to treat or prevent a disease in a subject by inducing immunity to the disease in the subject.

[0056]

[0120] For example, in some embodiments, the therapeutic compositions disclosed in the present invention can induce an immune response in a target against a disease. In some embodiments, such immunity can be induced via at least one of the following: innate immunity, mucosal immunity, systemic immunity, cellular immunity, humoral immunity, T cell immunity, production of systemic neutralizing antibodies, induction of IgG response, induction of IgA response, induction of IgM response, induction of T cell response, induction of mucosal IgA response in the lung and nasal compartments, induction of Th1 T cell response, induction of CD8+ T cell response, induction of CD4+ T cell response, induction of NK cell response, activation or inhibition of interferon gene (STING) pathway stimulants, or a combination thereof.

[0057]

[0121] In some cases, the compositions disclosed herein can induce mean dilution titers in the serum of a subject at a ratio of at least 1:25 and greater than 1:25 (e.g., IgG or IgA specific to a pathogen antigen or a part thereof). In some cases, the compositions disclosed herein can induce mean dilution titers in the bronchoalveolar lavage fluid (BALF) of a subject at a ratio of 1:25 to 1:50, 1:30 to 1:50, 1:40 to 1:50, 1:50 to 1:60, or at least 1:25, greater than 1:25, or less than 1:60 (e.g., IgG or IgA specific to a pathogen antigen or a part thereof).

[0058]

[0122] In some embodiments, the compositions of the present invention may induce or assist in the development of immunity to a disease in a subject, for example, by inducing an innate immune response in the subject to the disease. In some embodiments, the induced innate immune response may result in the activation of interferon regulators (IRFs), nuclear factor κB (NF-κB), or combinations thereof. In some embodiments, the induced innate immune response may result in the synthesis and secretion of type I and type III interferons (IFNs) and subsequent upregulation of IFN-stimulating genes (ISGs).

[0059]

[0123] In some embodiments, the therapeutic compositions disclosed in the present invention can be used to induce immunity in a subject against a disease, for example, via mucosal immunity and / or systemic immunity. In some embodiments, the therapeutic compositions disclosed in the present invention may be useful in inducing immunity in a subject via mucosal immunity, systemic immunity, and cellular immunity. In some embodiments, systemic immunity may be induced via the production of neutralizing antibodies against an antigen. In some embodiments, cellular immunity may be induced in spleen cells and / or lung cells. In some embodiments, mucosal immunity may be induced via the production of IgA in IgA-secreting cells in the nasal compartment and lungs, and in the spleen.

[0060]

[0124] The methods and therapeutic compositions disclosed in the present invention can offer numerous advantages in various embodiments. For example, in some embodiments, the therapeutic compositions disclosed in the present invention can be administered to large populations without requiring large clinical facilities.

[0061]

[0125] Furthermore, in some embodiments, the therapeutic compositions disclosed in the present invention can prevent the establishment of an early viral reservoir (e.g., in the nasal compartment) and can help control the spread of the virus between individuals and / or within individuals.

[0062]

[0126] In some embodiments, the therapeutic compositions disclosed in the present invention can correct interferon activation deficiency, which may be one of the primary mechanisms of respiratory virus-mediated escape. In addition, since the therapeutic compositions disclosed in the present invention can be used in some embodiments to induce one or more IgM, IgG, IgA, and T cell responses in a subject, the therapeutic compositions disclosed in the present invention can provide a versatile mucosal adjuvant for developing broad-spectrum therapeutic compositions against a number of pathogens, such as coronaviruses or other respiratory pathogens (e.g., other viral respiratory pathogens).

[0063]

[0127] In some embodiments, the methods and therapeutic compositions disclosed in the present invention can be applied to animals. In some embodiments, applications to animals include the treatment or prevention of diseases in various types of animals and other similar applications.

[0064] Formulation and administration

[0128] The compositions disclosed herein may be in various forms. In some cases, the compositions described herein may be delivered as a solubilized liquid. In some embodiments, the therapeutic compositions disclosed herein are suitable for intranasal and / or inhalation administration to a target. In some cases, intranasal delivery of the compositions disclosed herein can be used to target tissues of the nasal compartment. In some cases, inhalation administration of the compositions disclosed herein can be used to target tissues of the lung compartment.

[0065]

[0129] In some cases, the compositions described herein may be administered intranasally using a syringe or liquid dispensing device. In some cases, administration of the compositions described herein may involve the use of a spray nozzle, nebulizer, and / or atomizer. In some embodiments, the therapeutic compositions disclosed in the present invention may be self-administered.

[0066]

[0130] In some embodiments, the compositions disclosed in the present invention also include one or more stabilizers. In some embodiments, stabilizers include, but are not limited to, antioxidants, metal ion chelating agents, ultraviolet stabilizers, or combinations thereof.

[0067]

[0131] In some embodiments, the compositions disclosed in the present invention also include one or more surfactants. In some embodiments, surfactants include, but are not limited to, anionic surfactants, sugars, cationic surfactants, zwitterionic surfactants, nonionic surfactants, or combinations thereof.

[0068]

[0132] In some embodiments, the compositions disclosed in the present invention also include one or more excipients. In some embodiments, excipients include, but are not limited to, lactose, sucrose, starch powder, cellulose esters of alkanates, trehalose, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric acid and sulfate, gelatin, gum arabic, trehalose, sodium alginate, polyvinylpyrrolidone, polyvinyl alcohol, or combinations thereof.

[0069]

[0133] In some embodiments, the compositions disclosed herein may be lyophilized (e.g., freeze-dried). Lyophilization of the compositions (or components thereof) may increase the storage stability (e.g., shelf life) of the compositions described herein. In some cases, one or more components of the compositions disclosed herein may be lyophilized. In some cases, lyophilization of the compositions (or components thereof) may enable the easy preparation of the compositions, thereby enabling use in areas where material preparation facilities are not easily accessible (e.g., administration to subjects). For example, the modulators, lipid-based particles, and / or antigens described herein may be lyophilized, then rehydrated and mixed (e.g., as described herein) to formulate the compositions described herein at a site of administration to subjects that are far from permanent medical or pharmaceutical facilities. In some cases, the lyophilized compositions (or parts thereof, e.g., lyophilized particles, lyophilized antigens, or lyophilized modulators) described herein may be stored at 4°C. In some cases, the freeze-dried compositions (or parts thereof) described herein may be stored at 4°C and used for up to 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, or 12 months.

[0070]

[0134] The compositions disclosed in the present invention may be administered by a variety of methods. For example, in some embodiments, administration may be carried out by methods such as intravenous administration, intramuscular administration, intradermal administration, intraperitoneal administration, subcutaneous administration, spray-based administration, aerosol-based administration, intraocular administration, oral administration, intraocular administration, intratracheal administration, intranasal administration, inhalation administration, or a combination thereof.

[0071]

[0135] In some embodiments, the compositions disclosed in the present invention may be administered in a single dose. In some embodiments, the therapeutic compositions disclosed in the present invention may be administered in multiple doses. In some cases, a method of treating or preventing a disease in a subject (e.g., an animal subject) may involve administering 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 15-20, 20-25, 25-30, 30-40, 40-50, or more than 50 doses. In some cases, the compositions disclosed in the present invention may be administered to a subject (e.g., an animal subject) at multiple time points (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 time points). In some cases, a method of disclosure in the present invention may involve administering a first dose containing the composition disclosed in the present invention and a second dose containing the composition disclosed in the present invention to a subject. In some cases, the composition in the first dose is the same as the composition in the second dose. In some cases, the composition of the first dose differs from the composition of the second dose. In some cases, the method disclosed in the present invention may include administering the first dose and the second dose to a subject (e.g., an animal subject) at intervals of at least 4 hours, at least 6 hours, at least 12 hours, at least 24 hours, at least 36 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 14 days, or at least 28 days. In some cases, the method disclosed in the present invention may include administering the first dose and the second dose to a subject (e.g., an animal subject) at intervals of up to 6 hours, up to 12 hours, up to 24 hours, up to 36 hours, up to 2 days, up to 3 days, up to 4 days, up to 5 days, up to 6 days, up to 7 days, up to 14 days, or up to 28 days. In some cases, the method disclosed in the present invention may include administering the first dose and the second dose to a subject (e.g., an animal subject) at intervals of 6 hours, 12 hours, 24 hours, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 14 days, or 28 days.In some cases, the method disclosed in the present invention may include administering each dose of a multiple dose (for example, each dose of a multiple dose comprising one or more compositions disclosed in the present invention) to a subject (e.g., an animal subject) at least 4 hours, at least 6 hours, at least 12 hours, at least 24 hours, at least 36 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 14 days, or at least 28 days after the administration of the previous dose. In some cases, the method of disclosure of the present invention may include administering each dose of a multiple-dose group (for example, each dose of a multiple-dose group comprising one or more compositions of the disclosure of the present invention) to a subject (e.g., an animal subject) at a maximum of 6 hours, 12 hours, 24 hours, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 14 days, or 28 days after the administration of the previous dose. In some cases, the method of disclosure of the present invention may include administering each dose of a multiple-dose group (for example, each dose of a multiple-dose group comprising one or more compositions of the disclosure of the present invention) to a subject (e.g., an animal subject) at a maximum of 6 hours, 12 hours, 24 hours, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 14 days, or 28 days after the administration of the previous dose. In some cases, the composition is administered to the subject in two, three, four, five, or more than five doses. In some cases, the second, third, and fourth doses (e.g., of a four-dose treatment) are administered 12 to 36 hours after the previous dose. In some cases, the second, third, and fourth doses (e.g., of a four-dose treatment) are administered 1, 2, 4, 6, 8, 10, 12, 18, 24, 30, or 36 hours after the previous dose.

[0072]

[0136] In some cases, the compositions described herein (e.g., “NanoSTING” compositions comprising lipid-based particles, modulators, and antigens) may be formulated and / or administered as monotherapy agents (e.g., for treating diseases or conditions in a subject, e.g., diseases or conditions caused by exposure to a pathogen).

[0073]

[0137] The compositions or methods described herein (for example, for treating a disease or condition in a subject, for preventing a disease or condition in a subject, or for preventing the transmission of a disease or condition from a first subject to a second subject) may include nanoparticles (e.g., lipid-based nanoparticles) and modulators (e.g., pattern recognition receptor agonist proteins, e.g., STING agonists). In some cases, the compositions or methods comprising nanoparticles (e.g., lipid-based nanoparticles) and modulators may be antigen-deficient (e.g., as shown in Figures 33B, 33E, 34C, and 34D). In some cases, the modulator of an antigen-deficient composition or method comprising nanoparticles and modulators may be encapsulated within the nanoparticles. In some embodiments, the antigen-deficient compositions comprising nanoparticles and modulators may be administered to a subject (e.g., a human subject or a non-human mammalian subject) in the doses, dosage forms, and / or over the course of treatment or vaccination as described herein. For example, a composition containing nanoparticles and modulators but lacking an antigen can be administered to a subject (e.g., a human or non-human mammalian subject) before the subject is exposed to an infectious agent (e.g., a respiratory virus such as a virus, e.g., coronavirus, influenza virus, parainfluenza virus, or rhinovirus). In some cases, a composition containing nanoparticles and modulators but lacking an antigen can be administered to a subject (e.g., a human or non-human mammalian subject) before the subject develops a respiratory disease or condition (e.g., related to a respiratory virus) or, in some cases, cancer such as lung cancer, and / or before the symptoms of such cancer appear. In some cases, a composition containing nanoparticles and modulators but lacking an antigen can be administered to a subject (e.g., a human or non-human mammalian subject) after the subject has been exposed to an infectious agent (e.g., a respiratory virus such as a virus, e.g., coronavirus, influenza virus, parainfluenza virus, or rhinovirus).In some cases, compositions containing nanoparticles and modulators but lacking antigens can be administered to subjects (e.g., human or non-human mammalian subjects) after they have a respiratory disease or condition (e.g., related to respiratory viruses) or, in some cases, a cancer such as lung cancer, and / or after the onset of symptoms thereof. In some cases, compositions containing nanoparticles and modulators but lacking antigens can be administered to subjects intranasally. In some cases, compositions and methods containing nanoparticles and modulators but lacking antigens may be relatively inexpensive or their manufacture, storage, and / or preparation may not be logistically complex. In some cases, compositions containing nanoparticles and modulators but lacking antigens can be administered to subjects in combination with compositions containing nanoparticles, modulators, and antigens, for example, simultaneously, sequentially, or separately, as part of a single treatment or vaccination regimen.

[0074]

[0138] Compositions or methods described herein (for example, for treating a disease or condition in a subject, for preventing a disease or condition in a subject, or for preventing the transmission of a disease or condition from a first subject to a second subject) may include modulators described herein (for example, pattern recognition receptor agonist proteins, e.g., STING agonists). In some cases, compositions or methods comprising modulators may lack antigens and nanoparticles (e.g., liposomes). In some cases, modulators can be administered to a subject (e.g., a human subject or a non-human mammalian subject) without antigens or nanoparticles to treat or prevent a disease or condition in the subject (e.g., a disease or condition related to cancer or respiratory viruses or a respiratory disease). In some embodiments, compositions comprising modulators but lacking antigens or nanoparticles may be administered to a subject (e.g., a human subject or a non-human mammalian subject) in the doses, dosage forms, and / or over the course of treatment or vaccination as described herein. For example, a composition containing a modulator but lacking an antigen or nanoparticles can be administered to a subject (e.g., a human or non-human mammalian subject) before the subject is exposed to an infectious agent (e.g., a respiratory virus such as a virus, e.g., coronavirus, influenza virus, parainfluenza virus, or rhinovirus). In some cases, a composition containing a modulator but lacking an antigen or nanoparticles can be administered to a subject (e.g., a human or non-human mammalian subject) before the subject develops a respiratory disease or condition (e.g., related to a respiratory virus) or, in some cases, cancer such as lung cancer, and / or before the symptoms of such cancer appear. In some cases, a composition containing a modulator but lacking an antigen or nanoparticles can be administered to a subject (e.g., a human or non-human mammalian subject) after the subject has been exposed to an infectious agent (e.g., a respiratory virus such as a virus, e.g., coronavirus, influenza virus, parainfluenza virus, or rhinovirus).In some cases, compositions containing modulators but lacking antigens or nanoparticles can be administered to subjects (e.g., human or non-human mammalian subjects) after they have a respiratory disease or condition (e.g., related to respiratory viruses) or, in some cases, a cancer such as lung cancer, and / or after the onset of symptoms thereof. In some cases, compositions containing modulators but lacking antigens or nanoparticles can be administered intranasally to subjects. In some cases, compositions and methods containing modulators but lacking antigens or nanoparticles may be relatively inexpensive or their manufacture, storage, and / or preparation may not be logistically complex. In some cases, compositions containing nanoparticles and modulators but lacking antigens can be administered to subjects in combination with compositions containing nanoparticles, modulators, and antigens, for example, simultaneously, sequentially, or separately, as part of a single treatment or vaccination regimen.

[0075]

[0139] In some cases, the compositions of the disclosure of the present invention (for example, for treating a subject having a disease or condition, such as a respiratory disease, or for preventing a subject from contracting the disease or condition or transmitting the disease or condition to a second subject) may contain 0.1 μg to 200 μg of a modulator (for example, a STING pathway activator (e.g., a STING agonist)). In some cases, the compositions disclosed in the present invention are in amounts of 0.1 μg to 1 μg, 0.1 μg to 2 μg, 0.1 μg to 3 μg, 0.1 μg to 5 μg, 0.1 μg to 10 μg, 0.1 μg to 20 μg, 0.1 μg to 30 μg, 0.1 μg to 50 μg, 0.1 μg to 100 μg, 0.1 μg to 120 μg, 0.1 μg to 200 μg, 1 μg to 2 μg, 1 μg to 3 μg, 1 μg to 5 μg, 1 μg to 10 μg, and 1 μg to 20 μg. , 1μg~30μg, 1μg~50μg, 1μg~100μg, 1μg~120μg, 1μg~200μg, 2μg~3μg, 2μg~5μg, 2μg~10μg, 2μg~20μg, 2μg~30μg, 2μg~50μg, 2μg~100μg, 2μg~120μg, 2μg~200μg, 3μg~5μg, 3μg~10μg, 3μg~20μg, 3μg~30μg, 3μg~50μg, 3μg~100μg , 3μg~120μg, 3μg~200μg, 5μg~10μg, 5μg~20μg, 5μg~30μg, 5μg~50μg, 5μg~100μg, 5μg~120μg, 5μg~200μg, 10μg~ 20μg, 10μg~30μg, 10μg~50μg, 10μg~100μg, 10μg~120μg, 10μg~200μg, 20μg~30μg, 20μg~50μg, 20μg~100μg, 20μg It may contain a modulator (e.g., a STING pathway activator (e.g., a STING agonist)) in amounts of 120 μg to 120 μg, 20 μg to 200 μg, 30 μg to 50 μg, 30 μg to 100 μg, 30 μg to 120 μg, 30 μg to 200 μg, 50 μg to 100 μg, 50 μg to 120 μg, 50 μg to 200 μg, 100 μg to 120 μg, 100 μg to 200 μg, or 120 μg to 200 μg.In some cases, the compositions disclosed in the present invention may contain 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of modulator (e.g., STING pathway activator (e.g., STING agonist)). In some cases, the compositions disclosed in the present invention may contain at least 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of modulator (e.g., STING pathway activator (e.g., STING agonist)). In some cases, the compositions disclosed in the present invention may contain up to 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of modulators (e.g., STING pathway activators (e.g., STING agonists)).

[0076]

[0140] In some cases, the compositions of the disclosure of the present invention (for example, for treating a subject having a disease or condition, such as a respiratory disease, or for preventing a subject from contracting the disease or condition or transmitting the disease or condition to a second subject) may contain 0.1 μg to 200 μg of particles (for example, lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles). In some cases, the compositions disclosed in the present invention are in amounts of 0.1 μg to 1 μg, 0.1 μg to 2 μg, 0.1 μg to 3 μg, 0.1 μg to 5 μg, 0.1 μg to 10 μg, 0.1 μg to 20 μg, 0.1 μg to 30 μg, 0.1 μg to 50 μg, 0.1 μg to 100 μg, 0.1 μg to 120 μg, 0.1 μg to 200 μg, 1 μg to 2 μg, 1 μg to 3 μg, 1 μg to 5 μg, 1 μg to 10 μg, 1 μg to 20 μg, 1μg~30μg, 1μg~50μg, 1μg~100μg, 1μg~120μg, 1μg~200μg, 2μg~3μg, 2μg~5μg, 2μg~10μg, 2μg~20μg, 2μg~30μg, 2 μg~50μg, 2μg~100μg, 2μg~120μg, 2μg~200μg, 3μg~5μg, 3μg~10μg, 3μg~20μg, 3μg~30μg, 3μg~50μg, 3μg~100μg, 3μg~120μg, 3μg~200μg, 5μg~10μg, 5μg~20μg, 5μg~30μg, 5μg~50μg, 5μg~100μg, 5μg~120μg, 5μg~200μg, 10μg~2 0μg, 10μg~30μg, 10μg~50μg, 10μg~100μg, 10μg~120μg, 10μg~200μg, 20μg~30μg, 20μg~50μg, 20μg~100μg, 20μg The product may contain particles of ~120 μg, 20 μg~200 μg, 30 μg~50 μg, 30 μg~100 μg, 30 μg~120 μg, 30 μg~200 μg, 50 μg~100 μg, 50 μg~120 μg, 50 μg~200 μg, 100 μg~120 μg, 100 μg~200 μg, or 120 μg~200 μg (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles).In some cases, the compositions disclosed in the present invention may contain 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles). In some cases, the compositions disclosed in the present invention may contain at least 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles). In some cases, the compositions disclosed in the present invention may contain up to 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles).

[0077]

[0141] In some cases, a composition of the disclosure of the present invention comprising 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles) (for example, for treating a subject having a disease or condition, e.g., a respiratory disease, or for preventing a subject from contracting the disease or condition or transferring the disease or condition to a second subject) may also comprise 0.1 μg to 200 μg of a modulator (e.g., a STING pathway activator (e.g., a STING agonist)).In some cases, the compositions of the disclosure of the present invention, comprising 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles), are available in amounts of 0.1 μg to 1 μg, 0.1 μg to 2 μg, 0.1 μg to 3 μg, 0.1 μg to 5 μg, 0.1 μg to 10 μg, 0.1 μg to 20 μg, 0.1 μg to 30 μg, 0.1 μg to 50 μg, 0.1 μg to 100 μg, 0.1 μg to 120 μg, 0.1 μg to 200 μg, and 1 μg to 2 μg, 1μg~3μg, 1μg~5μg, 1μg~10μg, 1μg~20μg, 1μg~30μg, 1μg~50μg, 1μg~100μg, 1μg~120μg, 1μg~200μg, 2μg~3μg, 2μg~5 μg, 2μg~10μg, 2μg~20μg, 2μg~30μg, 2μg~50μg, 2μg~100μg, 2μg~120μg, 2μg~200μg, 3μg~5μg, 3μg~10μg, 3μg~20μg, 3μg ~30μg, 3μg~50μg, 3μg~100μg, 3μg~120μg, 3μg~200μg, 5μg~10μg, 5μg~20μg, 5μg~30μg, 5μg~50μg, 5μg~100μg, 5μg~120 μg, 5μg~200μg, 10μg~20μg, 10μg~30μg, 10μg~50μg, 10μg~100μg, 10μg~120μg, 10μg~200μg, 20μg~30μg, 20μg~50μg, 20 It may contain a modulator (e.g., a STING pathway activator (e.g., a STING agonist)) in amounts of μg to 100 μg, 20 μg to 120 μg, 20 μg to 200 μg, 30 μg to 50 μg, 30 μg to 100 μg, 30 μg to 120 μg, 30 μg to 200 μg, 50 μg to 100 μg, 50 μg to 120 μg, 50 μg to 200 μg, 100 μg to 120 μg, 100 μg to 200 μg, or 120 μg to 200 μg. In some cases, a composition of the disclosure of the present invention comprising 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles) may also comprise 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of modulators (e.g., STING pathway activators (e.g., STING agonists)).In some cases, a composition of the disclosure of the present invention comprising 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles) may contain at least 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of modulator (e.g., STING pathway activators (e.g., STING agonists)). In some cases, a composition of the disclosure of the present invention comprising 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles) may contain up to 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of modulator (e.g., STING pathway activators (e.g., STING agonists)).

[0078]

[0142] In some embodiments, the compositions of the disclosure of the present invention may contain multiple different antigens. For example, the compositions of the disclosure of the present invention may contain nucleocapsid proteins (N-proteins) and S-proteins (e.g., coronavirus spike proteins). In some cases, the compositions of the disclosure of the present invention may contain multiple types of single-class antigens. For example, the compositions of the disclosure of the present invention may contain monomeric antigens (e.g., monomeric S-proteins), trimeric antigens (e.g., trimeric S-proteins), chimeric antigens (e.g., chimeric S-proteins), and / or variants of antigens (e.g., mutant S-proteins).

[0079]

[0143] In some cases, the compositions of the disclosure of the present invention (for example, for treating a subject having a disease or condition, such as a respiratory disease, or for preventing a subject from contracting the disease or condition or transmitting the disease or condition to a second subject) may contain 0.1 μg to 200 μg of an antigen (for example, a nucleocapsid protein (N-protein), a spike protein (S-protein), or an RSV antigen protein). In some cases, the compositions disclosed in the present invention are in amounts of 0.1 μg to 1 μg, 0.1 μg to 2 μg, 0.1 μg to 3 μg, 0.1 μg to 5 μg, 0.1 μg to 10 μg, 0.1 μg to 20 μg, 0.1 μg to 30 μg, 0.1 μg to 50 μg, 0.1 μg to 100 μg, 0.1 μg to 120 μg, 0.1 μg to 200 μg, 1 μg to 2 μg, 1 μg to 3 μg, 1 μg to 5 μg, 1 μg to 10 μg, 1 μg to 20 μg, and 1 μg to 3 μg. 0μg, 1μg~50μg, 1μg~100μg, 1μg~120μg, 1μg~200μg, 2μg~3μg, 2μg~5μg, 2μg~10μg, 2μg~20μg, 2μg~30μg, 2μg~50μg, 2μg~100μg, 2μg~120μg, 2μg~200μg, 3μg~5μg, 3μg~10μg, 3μg~20μg, 3μg~30μg, 3μg~50μg, 3μg~100μg, 3μg~120μg, 3 μg~200μg, 5μg~10μg, 5μg~20μg, 5μg~30μg, 5μg~50μg, 5μg~100μg, 5μg~120μg, 5μg~200μg, 10μg~20μg, 10μg~30μg , 10μg~50μg, 10μg~100μg, 10μg~120μg, 10μg~200μg, 20μg~30μg, 20μg~50μg, 20μg~100μg, 20μg~120μg, 20μg~200μ It may contain an antigen (e.g., nucleocapsid protein (N-protein), spike protein (S-protein), or RSV antigen protein) in amounts of g, 30μg-50μg, 30μg-100μg, 30μg-120μg, 30μg-200μg, 50μg-100μg, 50μg-120μg, 50μg-200μg, 100μg-120μg, 100μg-200μg, or 120μg-200μg.In some cases, the compositions disclosed in the present invention may contain 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of antigen (e.g., nucleocapsid protein (N-protein), spike protein (S-protein), or RSV antigen protein). In some cases, the compositions disclosed in the present invention may contain at least 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of antigen (e.g., nucleocapsid protein (N-protein), spike protein (S-protein), or RSV antigen protein). In some cases, the compositions of the disclosure of the present invention may contain up to 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of antigen (e.g., nucleocapsid protein (N-protein), spike protein (S-protein), or RSV antigen protein). In some cases, a composition of the disclosure of the present invention containing 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles) (e.g., for treating a subject having a disease or condition, e.g., a respiratory disease, or for preventing a subject from contracting the disease or condition or transmitting the disease or condition to a second subject) may contain 0.1 μg to 200 μg of antigen (e.g., nucleocapsid protein (N-protein), spike protein (S-protein), or RSV antigen protein).In some cases, the compositions of the disclosure of the present invention, comprising 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles), are available in amounts of 0.1 μg to 1 μg, 0.1 μg to 2 μg, 0.1 μg to 3 μg, 0.1 μg to 5 μg, 0.1 μg to 10 μg, 0.1 μg to 20 μg, 0.1 μg to 30 μg, 0.1 μg to 50 μg, 0.1 μg to 100 μg, 0.1 μg to 120 μg, 0.1 μg to 200 μg, 1 μg to 2 μg, and 1 μg. g~3μg, 1μg~5μg, 1μg~10μg, 1μg~20μg, 1μg~30μg, 1μg~50μg, 1μg~100μg, 1μg~120μg, 1μg~200μg, 2μg~3μg, 2μg~5μg, 2μg~1 0μg, 2μg~20μg, 2μg~30μg, 2μg~50μg, 2μg~100μg, 2μg~120μg, 2μg~200μg, 3μg~5μg, 3μg~10μg, 3μg~20μg, 3μg~30μg, 3μg~5 0μg, 3μg~100μg, 3μg~120μg, 3μg~200μg, 5μg~10μg, 5μg~20μg, 5μg~30μg, 5μg~50μg, 5μg~100μg, 5μg~120μg, 5μg~200μg, 1 0μg~20μg, 10μg~30μg, 10μg~50μg, 10μg~100μg, 10μg~120μg, 10μg~200μg, 20μg~30μg, 20μg~50μg, 20μg~100μg, 20μg~120 It may contain an antigen (e.g., nucleocapsid protein (N-protein), spike protein (S-protein), or RSV antigen protein) in amounts of μg, 20μg-200μg, 30μg-50μg, 30μg-100μg, 30μg-120μg, 30μg-200μg, 50μg-100μg, 50μg-120μg, 50μg-200μg, 100μg-120μg, 100μg-200μg, or 120μg-200μg.In some cases, a composition of the disclosure of the present invention comprising 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles) may also comprise 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of antigen (e.g., nucleocapsid protein (N-protein), spike protein (S-protein), or RSV antigen protein). In some cases, a composition of the disclosure of the present invention comprising 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles) may also comprise at least 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of antigen (e.g., nucleocapsid protein (N-protein), spike protein (S-protein), or RSV antigen protein). In some cases, a composition of the disclosure of the present invention comprising 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles) may contain up to 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of antigen (e.g., nucleocapsid protein (N-protein), spike protein (S-protein), or RSV antigen protein).

[0080]

[0144] In some cases, a composition of the disclosure of the present invention comprising at least 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles) and at least 4 μg of antigen (for example, for treating a subject having a disease or condition, e.g., a respiratory disease, or for preventing a subject from contracting the disease or condition or transmitting the disease or condition to a second subject) may also comprise 0.1 μg to 200 μg of modulator (e.g., a STING pathway activator (e.g., a STING agonist)).In some cases, the compositions of the disclosure of the present invention comprising at least 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles) and at least 4 μg of antigen are available in concentrations of 0.1 μg to 1 μg, 0.1 μg to 2 μg, 0.1 μg to 3 μg, 0.1 μg to 5 μg, 0.1 μg to 10 μg, 0.1 μg to 20 μg, 0.1 μg to 30 μg, 0.1 μg to 50 μg, 0.1 μg to 100 μg, 0.1 μg to 120 μg, and 0. 1μg~200μg, 1μg~2μg, 1μg~3μg, 1μg~5μg, 1μg~10μg, 1μg~20μg, 1μg~30μg, 1μg~50μg, 1μg~100μg, 1μg~120μg, 1μg~200μg, 2μg~3μg, 2μg~5μg, 2μg~10μg, 2μg~20μg, 2μg~30μg, 2μg~50μg, 2μg~100μg, 2μg~120μg, 2μg~200μg, 3μg~5μg, 3μg~10μg, 3μg g~20μg, 3μg~30μg, 3μg~50μg, 3μg~100μg, 3μg~120μg, 3μg~200μg, 5μg~10μg, 5μg~20μg, 5μg~30μg, 5μg~50μg, 5μg~100μg , 5μg~120μg, 5μg~200μg, 10μg~20μg, 10μg~30μg, 10μg~50μg, 10μg~100μg, 10μg~120μg, 10μg~200μg, 20μg~30μg, 20μg~50 It may contain a modulator (e.g., a STING pathway activator (e.g., a STING agonist)) in the amounts of μg, 20μg-100μg, 20μg-120μg, 20μg-200μg, 30μg-50μg, 30μg-100μg, 30μg-120μg, 30μg-200μg, 50μg-100μg, 50μg-120μg, 50μg-200μg, 100μg-120μg, 100μg-200μg, or 120μg-200μg.In some cases, a composition of the disclosure of the present invention comprising at least 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles) and at least 4 μg of antigen may also comprise 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of modulator (e.g., STING pathway activator (e.g., STING agonist)). In some cases, a composition of the disclosure of the present invention comprising at least 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles) and at least 4 μg of antigen may also comprise at least 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of modulator (e.g., STING pathway activator (e.g., STING agonist)). In some cases, a composition of the disclosure of the present invention comprising at least 20 μg of particles (e.g., lipid-based particles (e.g., liposomes), e.g., lipid-based nanoparticles) and at least 4 μg of antigen may also comprise up to 0.1 μg, 1 μg, 2 μg, 3 μg, 5 μg, 10 μg, 20 μg, 30 μg, 50 μg, 100 μg, 120 μg, or 200 μg of modulator (e.g., STING pathway activator (e.g., STING agonist)).

[0081]

[0145] In some cases, the dose administered to a subject according to the composition or method described herein may include 0.1 μg to 20 μg of the composition described herein (e.g., a composition including a modulator and particles, or a composition including a modulator, particles, and an antigen). In some cases, the dose administered to a subject according to the composition or method described herein may include 0.1 μg to 0.5 μg, 0.1 μg to 1 μg, 0.1 μg to 2.5 μg, 0.1 μg to 5 μg, 0.1 μg to 7.5 μg, 0.1 μg to 9.3 μg, 0.1 μg to 10 μg, 0.1 μg to 15 μg, 0.1 μg to 20 μg, 0.5 μg μg~1μg, 0.5μg~2.5μg, 0.5μg~5μg, 0.5μg~7.5μg, 0.5μg~9.3μg, 0.5μg~10μg, 0.5μg~15μg , 0.5μg~20μg, 1μg~2.5μg, 1μg~5μg, 1μg~7.5μg, 1μg~9.3μg, 1μg~10μg, 1μg~15μg, 1μg~20μ g, 2.5μg~5μg, 2.5μg~7.5μg, 2.5μg~9.3μg, 2.5μg~10μg, 2.5μg~15μg, 2.5μg~20μg, 5μg~7 .5μg, 5μg~9.3μg, 5μg~10μg, 5μg~15μg, 5μg~20μg, 7.5μg~9.3μg, 7.5μg~10μg, 7.5μg~15μ The compositions described herein (e.g., compositions containing modulators and particles, or compositions containing modulators, particles, and antigens) may include g, 7.5 μg to 20 μg, 9.3 μg to 10 μg, 9.3 μg to 15 μg, 9.3 μg to 20 μg, 10 μg to 15 μg, 10 μg to 20 μg, or 15 μg to 20 μg. In some cases, the dose administered to a subject according to the compositions or methods described herein may include 0.1 μg, 0.5 μg, 1.0 μg, 1.2 μg, 2.3 μg, 2.5 μg, 4.7 μg, 5.0 μg, 7.5 μg, 9.3 μg, 10 μg, 15 μg, or 20 μg of the compositions described herein (e.g., compositions containing modulators and particles, or compositions containing modulators, particles, and antigens).In some cases, the dose administered to a subject according to the compositions or methods described herein may include at least 0.1 μg, 0.5 μg, 1.0 μg, 1.2 μg, 2.3 μg, 2.5 μg, 4.7 μg, 5.0 μg, 7.5 μg, 9.3 μg, 10 μg, 15 μg, or 20 μg of the compositions described herein (e.g., compositions containing modulators and particles, or compositions containing modulators, particles, and antigens). In some cases, the dose administered to a subject according to the compositions or methods described herein may include up to 0.1 μg, 0.5 μg, 1.0 μg, 1.2 μg, 2.3 μg, 2.5 μg, 4.7 μg, 5.0 μg, 7.5 μg, 9.3 μg, 10 μg, 15 μg, or 20 μg of the compositions described herein (for example, compositions containing modulators and particles, or compositions containing modulators, particles, and antigens).

[0082]

[0146] In some embodiments, the compositions disclosed herein may be administered in combination with other therapeutic treatments. In some embodiments, other therapeutic treatments may include, but are not limited to, immunotherapy, virology, targeted inhibition, radiotherapy, chemotherapy, or combinations thereof. In some cases, the compositions described herein may contain and / or be administered in a treatment regimen using adjuvants (e.g., one or more antibodies, one or more antiviral treatments, one or more vaccines, one or more small molecules, one or more nucleic acids, and / or one or more peptides or proteins, such as interleukins (e.g., IL-21)).

[0083] subject

[0147] The therapeutic compositions disclosed in the present invention can be administered to subjects in need. For example, in some embodiments, the subject is a mammal (e.g., human). In some embodiments, the subject is livestock. For example, the subject may be a dog or a cat. In some cases, the subject may be a cattle, horse, non-human primate, mouse, rat, rabbit, guinea pig, goat, sheep, giraffe, zebra, lion, tiger, or bear. In some embodiments, the subject may be a human. In some embodiments, the subject may be susceptible to or suffering from a respiratory infection. In some cases, the subject may be susceptible to or suffering from a condition caused by a respiratory virus. For example, the composition or method can be administered to a subject exposed to or infected with a respiratory virus, such as a respiratory RNA virus, such as coronavirus, influenza virus, respiratory syncytial virus, metapneumovirus, parainfluenza virus, or rhinovirus. In some embodiments, the subject may be susceptible to or suffering from cancer. In some cases, subjects may choose treatment as a result of exhibiting one or more symptoms of an infection by a pathogen or suffering from a disease (e.g., infection by a respiratory pathogen or suffering from a respiratory disease). For example, subjects may choose treatment based on having one or more symptoms such as persistent cough, elevated body temperature (e.g., higher than 100.4°C by frontal skin measurement), chills, joint pain, shortness of breath or difficulty regulating breathing, fluid accumulation in the lungs, fatigue, headache, loss of taste or smell, or a positive diagnostic test, such as a positive PCR test. In some cases, subjects may choose treatment with the compositions disclosed herein based on demographic risk factors, such as obesity, advanced age (e.g., 65 years or older), immunodeficiency, or pregnancy.In some cases, for example, if the subject's work involves close interaction with customers, frequent interaction with at-risk populations, handling of biological samples, or close contact with potentially infected individuals, the subject may choose treatment based on the risk of infection by a pathogen or the onset of a disease (e.g., infection by a respiratory pathogen or onset of a respiratory disease).

[0084] Treatment (procedure) or prevention (prevention) of a disease

[0148] Pathogens and cancer have caused significant health and economic concerns. For example, the viral infection caused by Severe Acute Respiratory Syndrome-associated Coronavirus 2 (SARS-CoV-2) led to the COVID-19 pandemic, which is currently the most urgent health and economic crisis globally. Furthermore, cancers such as lung cancer have a high mortality rate.

[0085]

[0149] In addition, treatment options for effectively treating and preventing cancer and infections caused by pathogens are extremely limited. For example, there are currently no drugs available to treat or prevent viral infections caused by SARS-CoV-2.

[0086]

[0150] In addition, many vaccines aimed at preventing infections caused by pathogens are intramuscular vaccines designed to induce systemic immunity without conferring innate immunity such as mucosal immunity or broad T-cell immunity. Such intramuscular vaccines have limitations because the nasal compartment is the first barrier that pathogens must overcome before spreading to the lungs.

[0087]

[0151] Furthermore, there is a high degree of unpredictability regarding the effectiveness of vaccine formulations. Of the vaccines that progress to Phase I trials, only about one-third ultimately receive FDA approval. This low success rate means that even with existing technologies to stimulate the immune system, developing effective immunity against any pathogen requires the correct design and optimization of antigens and adjuvants.

[0088]

[0152] Even if a vaccine receives FDA approval, it doesn't necessarily mean it will be effective. Vaccine development is a long process, and there are many challenges, even under the circumstances of the COVID-19 pandemic.

[0089]

[0153] Even if most platforms target spike proteins as antigens, optimizing the antigen design is desirable to ensure vaccine efficacy. The difficulty in selecting the appropriate vaccine design has been highlighted with HIV-1, hepatitis C, and malaria, and despite decades of effort and multiple candidates, vaccines remain difficult to obtain.

[0090]

[0154] Furthermore, with regard to respiratory pathogens, the nasal compartment is the first barrier that pathogens must overcome before spreading to the lungs. However, current intramuscular vaccines are designed to induce systemic immunity without conferring innate immunity such as mucosal immunity.

[0091]

[0155] Therefore, there is an urgent need for safe and long-lasting therapeutic compositions to treat and prevent various diseases, such as infectious diseases caused by pathogens and various types of cancer. For example, there is an urgent need for safe and long-lasting therapeutic compositions to treat or prevent pandemics caused by respiratory pathogens (e.g., viral infections caused by coronaviruses, e.g., SARS-CoV-2). Numerous embodiments of the disclosure of the present invention address the aforementioned needs.

[0092]

[0156] The therapeutic compositions and methods disclosed in the present invention can be used to treat or prevent diseases or conditions (e.g., diseases or conditions associated with pathogens). For example, in some embodiments, the disease may be an infectious disease caused by a pathogen. In some cases, the disease may be a respiratory disease. In some embodiments, the pathogen may be a respiratory pathogen. In some embodiments, the respiratory pathogen may be a virus. In some embodiments, the virus may be an influenza virus, influenza A virus, influenza B virus, parainfluenza virus, adenovirus, enterovirus, coronavirus, respiratory syncytial virus, rhinovirus, DNA virus, RNA virus, or a combination thereof.

[0093]

[0157] In some embodiments, the pathogen is a coronavirus. In some embodiments, the coronavirus may include, but is not limited to, severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome-associated coronavirus (SARSr-CoV), human coronavirus 229E (HCoV-229E), human coronavirus NL63 (HCoV-NL63), human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), Middle East respiratory syndrome-associated coronavirus (MERS-CoV), severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2), variants of SARS-CoV-2 (e.g., 20A.EU1, or spike variant D614G), or combinations thereof.

[0094]

[0158] Figure 40 provides an overview of some embodiments of the disclosure of the present invention. In some embodiments of the compositions and methods, subjects (e.g., mammalian subjects, e.g., humans, mice, hamsters, canids, felines, or non-human primates) can also be prophylactically treated from viral infections (e.g., SARS-CoV-2 coronavirus) by intranasal delivery of the compositions described herein (e.g., modulators, e.g., STING agonists and lipid-based nanoparticles) and antigens (e.g., spike proteins associated with, embedded therein, or coupled to the outer surface of lipid-based nanoparticles) as a single dose or as part of a multi-dose regimen. In some cases, treatment with the compositions can induce an immune response in the subject in one or more body compartments, e.g., the blood, spleen, lungs, and / or nasal compartment. As summarized in Figure 40, the compositions and methods described herein can, in some embodiments, induce an increase in anti-antigen IgG (e.g., anti-spike protein IgG) and / or anti-antigen IgA (e.g., anti-spike protein IgA) detectable in the lung tissue (e.g., BALF) or blood (e.g., serum) of the subject. In some cases, the compositions and methods described herein can increase the number of IgA-secreting B cells and / or antigen-specific T cells (e.g., spike protein-specific T cells), for example, in the spleen. In some cases, the increase in antigen-specific T cells can be detected in the lungs after administration of the compositions described herein to the subject. In some cases, the increase in anti-antigen IgA and / or the presence and / or activity of germinal center (GC) B cells or T follicular helper (Tfh) cells can be detected in the nasal compartment after administration of the compositions described herein to the subject.

[0095]

[0159] In some embodiments, the disease to be treated or prevented in the subject is cancer. In some embodiments, cancer may be tracheal cancer, lung cancer, bronchial cancer, epithelial cancer, blood cancer, breast cancer, melanoma, ovarian cancer, gynecological cancer, leukemia, lymphoma, prostate cancer, bladder cancer, colon cancer, glioma, sarcoma, glioblastoma, or a combination thereof. In some cases, cancer may be lung cancer. [Examples]

[0096] Example 1. Preparation and characterization of lipid-based particles

[0160] This example describes the preparation and characterization of lipid-based particles containing a STING agonist modulator and a spike protein antigen useful in compositions for treating (treating) or preventing (preventing) diseases in a subject (e.g., respiratory diseases). To facilitate efficient priming of the immune system within the respiratory compartment, the STING agonist was encapsulated in negatively charged liposomes to obtain a composition ("NanoSTING") containing the liposome, the STING agonist modulator, and the antigen associated with the surface of the liposome (see Figure 1).

[0097]

[0161] The liposomes were composed of DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a molar ratio of 10:1:1:1. 1,2-Dipalmitoyl-sn-Glycero-3-phosphocholine (DPPC), 1,2-Dipalmitoyl-sn-Glycero-3-phospho(1'-rac-glycerol) (DPPG), and 1,2-Dipalmitoyl-sn-Glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DPPE-PEG2000) were obtained from Avanti Polar Lipids (Alabaster, Alabama). Cholesterol was obtained from Sigma Aldrich (St. Louis, Missouri). To prepare liposomes, lipids were mixed in chloroform (CHCl3) and methanol (CH3OH), and the solution was evaporated at 45°C for approximately 80 minutes (min) using a vacuum rotary evaporator. The resulting lipid film was dried until all organic solvents had evaporated. The lipid film was hydrated by adding a pre-warmed cGAMP solution (0.3 mg / ml cGAMP in PBS buffer at pH 7.4). The STING agonist, 2'-3" cyclic guanosine monophosphate adenosine monophosphate (cGAMP), was obtained from Chemietek (Indianapolis, Indiana).

[0098]

[0162] The hydrated lipids were mixed for an additional 30 minutes at a temperature of 65°C, followed by a freeze-thaw cycle. The mixture was sonicated at 40 kHz for 60 minutes using a Branson ultrasonic generator. Untrapped free cGAMP was removed using an Amicon ultrafiltration unit with a molecular weight cutoff of 10 kDa. The cGAMP-liposomes were washed three times with PBS buffer. The cGAMP concentration in the filtrate was measured at 260 nm against a cGAMP calibration curve using a Citation 5 (BioTek) Take3 Micro-Volume absorbance analyzer (Figure 36A). The final concentration and encapsulation efficiency of cGAMP encapsulated in the liposomes were calculated by subtracting the concentration of free drug in the filtrate (the standard curve is shown in Figure 36B).

[0099]

[0163] The SARS-CoV-2 spike protein ("S-protein") monomer, or alternatively, the trimer, in a freshly hydrated, lyophilized form was mixed with a STINGa-liposome suspension at room temperature for 10 minutes to adsorb the protein onto the liposomes. The formulated compositions were stored at 4°C and used for up to 2 months. For stability determination, the STING agonist-liposome suspension was stored at 4°C for 11 months. Average particle size, polydispersity index, and zeta potential were characterized at room temperature using a Litesizer 500. Dynamic light scattering (DLS) analysis showed that the average particle size of the NanoSTING composition containing liposomes, the STING agonist ("STINGa") modulator, and cGAMP was 81 nm, with a polydispersity index of 0.21 (Figure 33B), while the size of blank liposomes lacking the STING agonist modulator or spike protein antigen was 110 nm (Figure 33A). The average particle size of NanoSTING compositions containing liposomes encapsulating STING agonist modulators and S-protein trimers associated with the outer surface of the liposomes was 105 nm, and the polydispersity index was 0.24 (Figure 33C). The average zeta potential of the liposomes was negative in both cases: with encapsulated STING agonist (-35 mV) (Figure 33E) and without encapsulated STING agonist (-68 mV) (Figure 33D). For NanoSTING compositions containing liposomes encapsulating STING agonist modulators and S-protein trimers associated with the outer surface of the liposomes, the average zeta potential of the liposomes was -30 mV (Figure 33F). Stability testing of NanoSTINGs showed that they were stable after storage at 4°C for 2 months (Figure 34A) and after storage for longer than 11 months at 4°C, as evidenced by the preservation of particle size and the absence of aggregates (Figure 34C). The surface charge of the liposomes also remained unchanged (-55mV) after 2 months at 4°C (Figure 34B) and after 11 months at 4°C (Figure 34D). Taken together, these results establish that negatively charged liposomes efficiently encapsulate STINGa and exhibit superior stability.

[0100]

[0164] The lyophilized recombinant trimer extracellular domain of the S-protein containing a mutation at the furin cleavage site was used as an immunogen (Figure 4A). As expected from the large-scale glycosylation of the S-protein, SDS-PAGE under reducing conditions confirmed that the protein had moved between 180 and 250 kDa (Figure 4B).

[0101]

[0165] A NanoSTING trimer S-protein composition (NanoSTING-trimer) formulation containing liposomes encapsulating trimer S-protein and STING modulators was prepared using a single-step mixing and immunization approach. The NanoSTING suspension was gently mixed with freshly rehydrated trimer S-protein while gently stirring at room temperature to adsorb the protein onto the liposomes. The adsorbed trimer S-protein (NanoSTING-trimer) exhibited an average particle size of 105 nm (Figure 33C) and an average zeta potential of -30 mV (Figure 33F), with a polydispersity index of 0.24, which was slightly larger and more negative than NanoSTING (81 nm, -35 mV). Taken together, these results indicate that the components of the composition are stable and readily formulated in the form of stable nanoparticle colloids.

[0102]

[0166] Since the trimer form of S-proteins can aggregate in solution in some cases, two different formulations of trimer S-proteins were tested: lyophilized and in solution stored at -20°C. The lyophilized form, after hydration and immediate measurement by DLS, showed no evidence of aggregation even after 6 months of storage (1 month at 25°C and 5 months at -20°C) (Figure 35B). However, the solution form of trimer S-proteins showed the presence of aggregated protein even after 1 week at -20°C (presence of a second particle peak >100 nm, polydispersity index = 0.28) (Figure 35A). These results illustrate that lyophilized proteins do not aggregate and can form the basis of stable formulations.

[0103] Example 2. Quantitative enzyme-linked immunosorbent assay (ELISA) analysis of NanoSTING-S composition

[0167] This example demonstrates the use of an S-protein quantitative ELISA to measure the adsorption of S-proteins from a NanoSTING composition to liposome particles.

[0104]

[0168] Antibody titers of anti-S-protein in serum or other biological fluids were determined using ELISA. Briefly, 1 μg / ml of spike protein (Sino Biological, Pennsylvania, USA) was coated onto ELISA plates (Corning, New York, USA) in PBS overnight at 4°C or 2 hours at 37°C. The plates were blocked at room temperature for 2 hours in PBS + 1% BSA (Fisher Scientific, Pennsylvania, USA) + 0.1% polysorbate 20 (Sigma-Aldrich, Tween20® from Maryland, USA). After washing, samples prepared in the same manner as in Example 1 were added at different dilutions. The captured antibodies were detected by horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Jackson ImmunoResearch Laboratories, 1:5,000; Pennsylvania, USA), anti-mouse IgA (Bethyl Laboratories, 1:10,000; Texas, USA), and detection antibodies against mouse IgA from a mouse total IgA ELISA kit from Invitrogen (California, USA) (1:250). A positive control (anti-S IgG) was obtained from Abeomics (California, USA).

[0105]

[0169] To estimate the proportion of protein adsorbed onto liposomes, trimer S-protein (10 μl, 1 μg / μl) was gently mixed with NanoSTING (20 μg) and incubated at room temperature for 10 minutes. The mixture was centrifuged at 20,000 × g for 40 minutes to separate the pellet, and the supernatant was removed. The pellet was resuspended in PBS (25 μl) and centrifuged again to collect the pellet. All supernatants were combined and measured by volume. The total S-protein, the pellet fraction of deposited adjuvant containing S-protein, and the combined supernatant fraction were quantified using quantitative S-protein ELISA. The results of the quantitative S-protein ELISA confirmed that 61.5% of the S-protein (average of two independent protein preparations) was adsorbed onto liposomes.

[0106] Example 3. In vivo toxicity testing

[0170] This example shows an analysis of the effects on body weight, morbidity, and excessive inflammatory symptoms in mice treated with the composition prepared as described in Example 1.

[0107]

[0171] I purchased 7-9 week old female BALB / c mice from Charles River Laboratories. Prior to single-dose administration, mice were anesthetized by intraperitoneal injection of ketamine and xylazine according to the following scheme: (1) The vehicle-only group was administered 20 μg of liposomes and modulator without spike protein antigen; (2) The control group was administered 10 μg of trimer spike protein (S-protein); (3) The NanoSTING-trimer group was administered a NanoSTING-trimer composition containing 20 μg of trimer spike protein associated with liposomes encapsulating 20 μg of STING agonist cGAMP, formulated as described herein; (4) The monomer-STINGa group was administered a NanoSTING-monomer composition containing 4 μg of monomer spike protein associated with liposomes encapsulating 20 μg of STING agonist cGAMP, formulated as described herein (see Figures 3 and 5A). Over a 14-day period, no weight loss was observed in mice administered with a composition containing only liposomes and modulators without spike protein antigen (Figure 5B), mice administered with spike protein antigen alone (Figure 5C, black box), or mice administered with a composition containing liposomes along with modulators and antigens (Figure 5C, clover-shaped data points).

[0108] Example 4. In vivo response to administration of NanoSTING trimer composition

[0172] This example demonstrates the in vivo IgG, IgA, and T cell responses following administration of the NanoSTING trimer composition described herein.

[0109]

[0173] Two groups of mice were treated by intranasal administration of either a combination of spike protein trimer antigens adsorbed onto liposomes encapsulating a STING agonist modulator (NanoSTING-trimers prepared according to Example 1) or the spike protein trimer antigen itself (control), according to the method shown in Figure 5A. No animals exhibited any clinical symptoms, such as weight loss. Seven days after immunization (d7), 100% of the mice treated with NanoSTING-trimers underwent seroconversion, and robust anti-SIgG levels were detected at a mean dilution titer of 1:640 (Figure 5D). On day 15 (d15), serum concentrations of anti-S IgG antibodies increased, and a mean dilution titer of 1:4,400 was detected (Figure 5E). Measurements using a GFP-reporter-based pseudovirus neutralization assay (SARS-CoV-2, Wuhan-Hu-1 pseudotype) confirmed that serum anti-S antibodies were neutralized at an average inhibitory dose of 50% (ID50) in a 1:414 ratio (Figure 5M).

[0110]

[0174] Reporter viruses expressing the SARS-CoV-2 spike protein were generated as follows. To determine the neutralizing antibody titer in immunized mice, a SARS-CoV-2-S pseudotyped lentiviral system was used as a substitute for SARS-CoV-2 infection. PsV particles were generated by cotransfecting stable ACE-2 and TMPRSS2-expressing 293T cells with the viral envelope protein expression plasmid pCAGGS containing pLVX-AcGFP1-C1, pMDLg / pRRE, pRSV-Rev, and SARS-CoV-2, or the plasmid pMD2.G expressing the Wuhan-Hu-1 spike glycoprotein gene or the VSV-G envelope. 293T cells stably expressing the SARS-CoV-2 receptor human angiotensin-converting enzyme II (ACE2) and the plasma membrane-bound type II transmembrane serine protease, TMPRSS2 (293T / ACE2-TMPRSS2), were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum. The SARS-CoV-2 S-protein pCAGGS expression plasmid, containing the SARS-CoV-2 and Wuhan-Hu-1 spike glycoprotein genes, was obtained from BEI Resources (Manassas, Virginia, USA). Plasmids encoding a lentiviral vector expressing GFP, the helper plasmids pMDLg / pRRE, pRSV-Rev, and pMD2.G, encoding the VSV-G protein, were obtained from Addgene (Watertown, Massachusetts, USA). PsV particles in the supernatant were collected 48 hours after transfection, filtered, and stored at -80°C. The dose titer of PsV was determined by infecting ACE-2 and TMPRSS2-expressing 293T cells for 48 hours using the Celigo imaging system for imaging and counting virus-infected fluorescent cells. Viral titer was expressed as fluorescent focus forming units (FFUs) per well.

[0111]

[0175] The SARS-CoV-2 neutralizing antibody (Nab) titration assay was performed as follows. 293T cells expressing ACE2-TMPRSS2 were cultured overnight at a concentration of 1×10 4 cells per well in 100 μl of complete medium in half of the area of a 96-well plate compatible with the Nexcelom Celigo imager. On the day of the assay, heat-inactivated serum from mice was thawed and serially diluted 2-fold at 6 points from 1:20 to 1:640 with serum-free DMEM. In a 96-well plate, 50 μl of the diluted serum was mixed with 50 μl of a PsV expressing SARS-CoV-2 spike expressing GFP (150 - 300 FFU / well) and incubated at 37°C for 1 hour. After 1 hour, this mixture was added to 293T cells expressing ACE2-TMPRSS2 and incubated for 48 hours. Infection of the target cells was determined by imaging and counting FFU / well using the Celigo imaging system. Each sample was tested in triplicate wells. A SARS-CoV-2 spike S1 rabbit Mab (clone number 007, Sinobiological, Wayne, PA) was used as a positive control for neutralizing activity, and a PsV expressing VSV-G was used as a negative control for the specificity of the neutralizing function. The 50% inhibitory dose (ID50) titer of the NAb was calculated using non-linear regression (GraphPad Prism, California, USA).

[0112]

[0176] Since IgA-mediated protection may be an element of mucosal immunity against respiratory pathogens, the IgA response in antibody-secreting cells (ASCs) in the spleen at day 15 was analyzed by the ELISPOT assay. IgA-secreting cells were detected using mouse IgG / IgA dual-color ELISPOT from Immunospot (Ohio, USA) according to the manufacturer's instructions. For total IgA-secreting cells in the spleen, splenocytes were thawed, inoculated, and immediately captured on antibody-coated ELISPOT plates. Cells were incubated at 37°C for 16–18 hours, followed by color development. For cells producing anti-S IgA, thawed splenocytes were cultured at 4 million cells / ml in complete medium [RPMI-1640 (Corning, New York, USA) + 10% fetal bovine serum (R&D System, Minnesota, USA), 100 μg / ml Normocin (Invivogen, California, USA), 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES] and B-Poly-S (1:1000 dilution). Wells were coated overnight at 4°C with 10 μg / ml spike protein (Sinobiological, Pennsylvania, USA). The splenocytes were washed and implanted onto plates at 37°C for 16–18 hours. Figures 5-I and 5J show the quantification of antibody-secreting cells (ASCs) secreting IgA and S-protein-specific IgA, respectively, as detected using the ELISpot (enzyme-linked immunosorbent spot) assay. Mice treated with NanoSTING trimers showed an increased number of ASCs secreting total IgA (Figure 5-I) and S-protein-specific IgA (Figure 5J) compared to the control group.

[0113]

[0177] Because T cell responses may contribute to protection independent of antibody responses, T cell responses in treated mice were evaluated using a pool of 15mers targeting highly conserved regions of the S-protein between SARS-CoV and SARS-CoV-2 (Figure 5P). The IFN-γ ELISpot assay was performed using the mouse IFN-γ ELISpot Basic Kit (ALP) according to the manufacturer's instructions (Mabtech, Virginia, USA). Frozen splenocytes or lung cells were thawed and inoculated into ELISPOT plates without further culture (1 × 10⁶ cells per well). 5 ~3×10 5 Splenocytes were incubated with a spike protein peptide pool at 1.5 μg / ml / peptide (Miltenyi Biotec, Germany) at 37°C for 16-18 hours. ELISpot plates were read using an ImmunoSpot® S6 Micro analyzer. On day 15, all five animals immunized with NanoSTING trimers showed a splenic T cell response, with 10 cells. 6 The average number of IFNγ spots per cell was 144 (Figure 5-O). In summary, these results indicate that a single intranasal administration using NanoSTING trimer induced robust serum neutralizing antibody and T cell responses.

[0114]

[0178] These experiments were repeated using trimer S-protein to track the rate of the immune response over the long term. Groups of mice were vaccinated with either the trimer form of S-protein or the adjuvant alone, and serum was sampled every 7 days for 24 days. Consistent with previous experiments, early seroconversion was observed at anti-S IgG levels with a mean dilution titer of 1:1440. The anti-S IgG response was 1:8000 on day 14 and changed only slightly on day 24 (1:12,000) (Figures 5G and 5H). IgG concentrations in bronchoalveolar lavage fluid (BALF) also increased in immunized animals on day 24 (median 1:40) (Figure 5F).

[0115]

[0179] IgA concentrations were evaluated in the blood and lungs. Serum anti-S IgA concentrations (dimers in mice) were observed at an average dilution titer of 1:80 (Figure 5K). IgA concentrations also increased in BALF (Figure 5L). Finally, it was confirmed that antibodies in the lungs were neutralized at an average inhibitory dose of 50% (ID50) at 1:213 (Figure 5N). In summary, these results establish that the NanoSTING trimer induces comprehensive cellular, systemic, and mucosal immunity.

[0116] Example 4. SARS-CoV-2 neutralizing antibody (Nab) titration assay

[0180] This example demonstrates an experiment investigating how a localized inductive response within the airway can trigger prolonged local immunity against inhaled pathogens.

[0117]

[0181] Nasopharyngeal lymphoid tissue (NALT) was collected at euthanasia from animals treated with NanoSTING trimer ("Trimer-STINGa") and animals treated with spike protein trimer alone. Nasopharyngeal lymphoid tissue (NALT) was isolated from mice after euthanasia, and erythrocytes were lysed by incubation in ACK lysis buffer (Thermo Fisher Scientific, Waltham, Massachusetts) for 3 minutes. NALT samples were converted to single-cell suspensions, sorted into live single-cell populations using flow cytometry, and subjected to scRNA-seq analysis (Figure 6A). Subsequently, the single-cell suspensions were washed with PBS, resuspended in PBS + 2% FBS, and exposed to 50 nM Helix NP Blue (BioLegend, San Diego, California) for live / dead cell detection.

[0118]

[0182] Live cells were sorted using a BD FACSMelody cell sorter (BD Biosciences, San Jose, California). The flow cytometry gating strategies used in this method are shown in Figures 6B, 6C, and 6D. Each group of NALT cells was separately labeled using a sample tag from the BD Mouse Immune Single-Cell Multiplexing Kit (BD Biosciences, San Jose, California) according to the protocol. Library preparation was then initiated from a mixture of approximately 6,000 cells (3,000 cells from each group). The whole transcriptome was prepared using the BD Rhapsody System according to the BD mRNA Whole Transcriptome Analysis (WTA) and Sample Tag Library Preparation Protocol. The final library quality and quantity were assessed using an Agilent 4200 TapeStation system with Agilent D5000 ScreenTape (Agilent Technologies, Santa Clara, California) and a Qubit fluorometer with a Qubit dsDNA HS assay, respectively. The final libraries were diluted to 3 nM and sequenced using a HiSeq PE150 sequencer (Illumina, San Diego, California). After filtering, a total of 1,398 scRNA-seq profiles were obtained.

[0119]

[0183] By utilizing homogeneous manifold approximation and projection (UMAP), B cells, T cells, NK cells, and bone marrow subpopulations were identified (Figure 7A). Subpopulations were confirmed using established lineage markers for B cell subpopulations (Figures 7B, 7C, 7D), T cell subpopulations (Figures 7E, 7F, 7G), NK cell subpopulations (Figures 7H, 7-I, 7J), and bone marrow subpopulations (Figures 7K, 7L, 7M). More than 95% of scRNA-seq yielded both control and NanoSTING trimer groups corresponding to T and B cells. Detailed analyses were performed on these subsets of immune cells.

[0120]

[0184] As shown in Figures 8A, 8B, and 8C–9M, we identified the following four B cell clusters: naive B cells expressing Cd19 (see Figure 9A), Ms4a1 (CD20) (see Figure 9B), and Ighm (see Figure 9C); germinal center B cells (GC) expressing Cd69 (see Figure 8C), Cd38 (see Figure 8D), Cd83 (see Figure 8E), Cxcr4 (see Figure 8F), Zfp36 (see Figure 8G), Erg1 (see Figure 8H), Egr3 (see Figure 9K), Irf4 (see Figure 9D), Fosb (see Figure 9G), Jun (see Figure 9H), and Fos (see Figure 9M). B cells; intermediate B cell clusters including activated B cells expressing Cd38 (see Figure 8D); and ASCs (plasmablasts) expressing Sec61b (see Figure 9F), Casp3 (see Figure 9L), and Tram1 (see Figure 9-I) but lacking Ms4a1 (CD20) expression (see Figure 9B). Consistent with NALT's role as an effector site rather than an inductive site, a very small subpopulation of IgA (Igha)-expressing cells was detected on day 15 post-administration (see Figure 9J). Comparison between the control and NanoSTING-trimer groups showed a robust increase in GC B cell frequency accompanied by a decrease in naive B cells (Figure 8B). These results suggest that successful intranasal vaccination promoted the differentiation of GC-like B cells.

[0121]

[0185] Next, we investigated whether T cells within NALT support B cell differentiation. Three clusters were identified within the T cells: the first was a subpopulation of CD8+ T cells expressing Cd8a (see Figure 11B), and the second was a subpopulation of CD8+ T cells expressing a subpopulation of CD4+ T cells (see Figure 10A). CD4+ T cells were classified as naive T cells expressing Cd4 (see Figure 11A) and Npm1 (see Figure 11E); and T follicular helper-like cells (Tfh) expressing Cd69 (see Figure 10C), Il6ra (see Figure 10D), Nr4a1 (Nur77) (see Figure 10F), Tcf7 (TCF1) (see Figure 10G), Lef1 (see Figure 10H), Il7r (see Figure 11D), Fos (see Figure 11F), and Jun (see Figure 11G), and also expressing memory markers Cd27 (see Figure 10E) and Cd28 (see Figure 11C). A significant difference between the control and NanoSTING-trimer groups was an increased Tfh / naive CD4+ T cell ratio (Figure 10B).

[0122]

[0186] Since GC B cells and Tfh cells are representative of the dominant clusters in NanoSTING-trimeric NALT, the nature of interactions between these cells was investigated in more detail. First, intercellular interactions between different B and T cell clusters in NALT were visualized. Tfh cells were the dominant interacting cell type and strongly interacted with GC B cell clusters (Figure 12A). To investigate interactions at the molecular level, mouse genes were converted to their human counterparts, and interacting protein pairs were matched using CellPhoneDB. Briefly, T cells and B cells were classified into 14 cell types by their subpopulations and groups (treated, or trimer-STINGa). Ligand-receptor pairs with p-values ​​> 0.05 according to statistical tests calculated in CellPhoneDB were filtered out to evaluate relationships between different cell types that had significant pairs. Several well-established receptor-ligand pairs known to promote interaction between GC B cells and Tfh cells, BAFFR(TNFRSF13C)-BAFF(TNFSF13B); ICOSLG-ICOS; CD40-CD40L; and IL21-IL21R, were mutually detected in B cells and Tfh cells within NALT (Figure 12B). These results suggest that, upon immunization with NanoSTING trimers, NALT promotes GC-like T cell-dependent activation and B cell differentiation, which in turn can promote sustained immunity in the respiratory compartment.

[0123]

[0187] These results indicate that the NanoSTING composition containing the antigen may also contain an intranasal subunit vaccine, which can induce systemic neutralizing antibodies, mucosal IgA responses in the lung and nasal compartments, and Th1 T cell responses in mouse lungs. Single-cell RNA sequencing confirms the coexistence of T and B cell responses in a germinal center-like manner within nasopharyngeal-associated lymphoid tissue (NALT), confirming its role as an inducible site for immunity. The ability to induce immunity in the airways has the potential to prevent early colonization of infection in an individual and prevent disease transmission throughout the human population.

[0124] Example 5. Response to NanoSTING-S administration in the lung and nasal compartments

[0188] This example demonstrates the T cell response in the lung compartment and the IgA response in the nasal compartment in response to in vivo administration of the NanoSTING composition disclosed herein.

[0125]

[0189] To investigate whether monomeric spike protein (S-protein) could also induce a comprehensive immune response, monomeric forms of the S-protein containing a pair of mutations (Lys986Pro and Val987Pro) that mutate and stabilize the furin binding site were used (Figure 13A). SDS-PAGE of the monomeric protein showed a band between 130 and 180 kDa (Figure 13B). Each of the four mice was treated with a NanoSTING monomeric composition containing monomeric spike protein (S-protein) or monomeric spike protein associated with liposomes encapsulating the STING agonist cGAMP. The NanoSTING monomeric composition was formulated using monomeric spike protein instead of trimeric spike protein, using the same protocol as described in Example 1. No weight loss was observed in any of the animals (Figure 14). On day 15, seroconversion occurred in 100% of the animals, and the mean serum concentration of anti-S protein ("anti-S") IgG antibody was 1:1000 (Figure 13C). Neutralization of serum anti-S protein ("anti-S") antibody was confirmed at an mean ID50 of 1:188 (Figure 13D).

[0126]

[0190] Antibody responses in the nasal compartment and total IgA in nasal lavage fluid were measured by ELISA from two animals. Both nasal lavage fluids also contained detectable anti-S IgA antibodies at an average concentration of 7 ng / ml (Figure 13F). Consistent with monomer-STINGa's ability to induce a mucosal immune response, this also confirmed the detection of ASCs secreting S-specific IgA in the spleen of these mice (Figure 15). These results establish that vaccination with monomer-STINGa induces systemic immunity, T cell responses in the lungs and spleen, and a mucosal IgA response.

[0127]

[0191] Animal models have shown that T cells in the lungs are necessary for protection against lung infections caused by respiratory pathogens. Therefore, the S-protein-specific T cell response in the lungs of vaccinated animals was evaluated using a conserved peptide pool (Figure 5P). The T cell response was observed in cells 10 in the spleen. 6 IFNγ was detected on average at 100 spots per cell in the lungs, with 10 cells detected 15 days after treatment. 6 It was detected on average from 206 IFNγ spots per individual (Figure 13E).

[0128]

[0192] In summary, these results establish that intranasal administration using NanoSTING monomers also induced robust serum neutralizing antibody and T cell responses in both the lungs and spleen.

[0129] Example 6: Preparation and Characterization of NanoSTING-N Composition

[0193] This example describes the preparation and characterization of a composition containing a STING agonist modulator and a nucleocapsid antigen useful in treating or preventing diseases in a subject (e.g., respiratory diseases). To facilitate efficient priming of the immune system within the respiratory compartment, the STING agonist was encapsulated in a negatively charged liposome to obtain a composition ("NanoSTING-N") containing the liposome, modulator, and nucleocapsid antigen associated with the surface of the liposome (see Figure 16).

[0130]

[0194] The liposomes were composed of DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a molar ratio of 10:1:1:1. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-Dipalmitoyl-sn-glycero-3-phospho(1'-rac-glycerol) (DPPG), and 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DPPE-PEG2000) were obtained from Avanti Polar Lipids (Alabaster, Alabama). Cholesterol was obtained from Sigma-Aldrich (St. Louis, Missouri). To prepare liposomes, lipids were mixed in chloroform (CHCl3) and methanol (CH3OH), and the solution was evaporated at 45°C for approximately 80 minutes (min) using a vacuum rotary evaporator. The resulting lipid film was dried until all organic solvents had evaporated. The lipid film was hydrated by adding a pre-warmed cGAMP solution (0.3 mg / ml cGAMP in PBS buffer at pH 7.4). The STING agonist, 2'-3" cyclic guanosine monophosphate adenosine monophosphate (cGAMP), was obtained from Chemitech (Indianapolis, Indiana).

[0131]

[0195] Hydrated lipids were mixed for an additional 30 minutes at a temperature of 65°C, followed by a freeze-thaw cycle. The mixture was sonicated for 60 minutes at 40 kHz using a Branson sonicator. SARS-CoV-2 (2019-nCoV) nucleocapsid recombinant protein (N-protein) was purchased from BEI Resources (Virginia, USA, number NR-53797) and tested in combination with STING-liposome suspension at two different doses (10 μg and 20 μg). The recombinant N-protein was mixed with NanoSTING liposomes encapsulating cGAMP to adsorb the protein onto the liposomes. Untrapped free cGAMP was removed using an Amicon ultrafiltration unit with a molecular weight cutoff of 10 kDa. The cGAMP-liposomes were washed three times with PBS buffer. The cGAMP concentration in the filtrate was measured at 260 nm using a Citation 5 (Biotech) Take3 microvolume absorbance analyzer against a cGAMP calibration curve (Figure 36A). The final concentration and encapsulation efficiency of cGAMP encapsulated in liposomes were calculated by subtracting the concentration of the free drug in the filtrate (the standard curve is shown in Figure 36B). The NanoSTING-N composition was maintained at room temperature to allow protein adsorption onto the liposomes. The formulated NanoSTING-N composition was stored at 4°C and used for up to 2 months. These results suggest that the formulated N-protein STING-liposome vaccine exists in a colloidal form of nanoparticles.

[0132]

[0196] Figure 18 shows a schematic diagram of the SARS-CoV-2 N-protein, demonstrating that it consists of a nucleic acid (RNA) binding domain, a C-terminal dimerization domain, and three essentially disordered domains that can facilitate phase separation with nucleic acids (Figure 18). Recombinant N-protein derived from insect cells was used as an immunogen, and a dominant band with a size of 47 kD was confirmed by SDS-PAGE (Figure 19).

[0133] Example 7: Effect of NanoSTING composition on interferon response in vitro

[0197] This example demonstrates experimental confirmation that NanoSTING induces an interferon regulatory factor (IRF) response using THP-1 monocyte cells that stably express luciferase secreted downstream of an IRF-responsive promoter.

[0134]

[0198] THP-1 dual cell lines (in vivogen) were cultured in a humidified incubator at 37°C and 5% CO2 and grown in RPMI / 10% FCS (Corning, New York, USA). The THP-1 dual cell line cultures were supplemented with the respective selective agents from in vivogen (100 μg / ml zeosin + 10 μg / ml blastosidine) and the corresponding selective cell growth inhibitors.

[0135]

[0199] At the start of a cell stimulation experiment including luciferase reporter enzyme detection, THP-1 dual cells were introduced into a 96-well plate with 180 μl of growth medium, containing 1 × 10 cells. 5Cells were cultured in cells / well. Serial dilutions of NanoSTING-N were prepared in growth medium, and the cells were then incubated at 37°C for 24 hours in the presence of NanoSTING-N at concentrations of 1.2 μg, 2.3 μg, 4.7 μg, and 9.3 μg. For detection of IRF activity, 10 μl of culture supernatant per well was collected at 6, 12, and 24-hour time points and transferred to a white (opaque) 96-well plate. 50 μl of QU anti-Luc(trademark) (in vivogen) substrate solution was added per well, and immediately thereafter, luminescence was measured (in relative luminescence (RLU)) using a Cytation 7 instrument (Bio-Tek Instruments, Inc.). Figure 27 shows the quantification of the interferon response coefficient (IRF) response in THP-1 dual cells in response to poly(dA:dT) ("poly(dA:dT) / LV"), a type I interferon inducer conjugated with the cationic lipid-based transfection reagent LyoVec® (In Vivogen), at 6, 12, and 24 hours after exposure to 1 μg of poly(dA:dT) / LV.

[0136]

[0200] Reaction kinetics were measured over 24 hours by contacting THP-1 dual cells and measuring luciferase activity in the supernatant (Figure 27). THP-1 luciferase secretion was observed only at low levels at 6 hours, increased by more than an order of magnitude at 12 hours at all concentrations of NanoSTING-N, and reached the maximum observed level at 24 hours (Figure 17). At 24 hours, all concentrations of NanoSTING-N showed similar THP-1 luciferase secretion.

[0137] Example 8: In vitro nucleocapsid DNA binding assay

[0201] This example demonstrates DNA binding studies performed to determine the ability of an N-protein nucleocapsid to functionally associate with plasmid DNA.

[0138]

[0202] Branched-strand PEI was used as a positive control (Sigma Chemical Co., St. Louis, Missouri, No. 408727). DiYO-1 (AAT Biorequest, No. 17579) and plasmid (pMB57.6)-DNA complexes were mixed with equal volumes of DNA and DiYO-1, a bis-intercalate fluorophore whose quantum efficiency increases by several orders of magnitude when bound to ds-DNA (in 20 mM HEPES, 100 mM NaCl, pH=7.4) to achieve final concentrations of 400 nM and 8 nM, respectively. The solutions were left at room temperature for 5 hours before use. PEI was then added to the DNA-DiYO-1 solution at different concentrations (R=0, 1, 2, 5, where R is the molar ratio of PEI nitrogen to DNA phosphate), vortexed for 1 minute, and left to equilibrate for 2 hours. The fluorescence intensity of the solution was measured at excitation and emission wavelengths of 470 nm and 510 nm, respectively (Figure 20B). This procedure was repeated using SARS-CoV2 nucleocapsid (N-protein) instead of PEI (Figure 20A). In these experiments, the nucleocapsid (N-protein) was added to the DNA-DiYO-1 solution at concentrations of 0.1 and 0.5 μM.

[0139]

[0203] The N-protein was able to quench the fluorescence of the DNA-DiYO-1 complex in a concentration-dependent manner (Figure 20A). At a concentration of 0.5 μM, the N-protein reduced the fluorescence intensity to a level comparable to that of polyethyleneimine (PEI), a known synthetic polycationic DNA condenser with an R=5 value (e.g., 96.3%) (Figure 20B). These results confirm that recombinant N-protein is a promising binding agent for dsDNA.

[0140] Example 9: Induction of humoral response using NanoSTING-N composition

[0204] This example demonstrates an in vivo test of the effect of the NanoSTING-N composition on humoral responses in mice.

[0141]

[0205] Female 7-9 week old BALB / c mice were purchased from Charles River Laboratories. Prior to administration of the composition, the mice were anesthetized by intraperitoneal injection of ketamine and xylazine. The animals were treated via a single intranasal administration of one of two different concentrations of the NanoSTING-N composition, containing 20 μg of liposomal-STING adjuvant for immunization and either 10 μg or 20 μg of nucleocapsid protein (NanoSTING-N10 and NanoSTING-N20, respectively).

[0142]

[0206] After administration of the NanoSTING-N composition, the body weight of the animals was measured every 7 days for 4 weeks. No animals treated with NanoSTING-N10 or NanoSTING-N20 were observed to experience weight loss or significant abnormalities over 27 days (Figure 28).

[0143]

[0207] Serum was collected from subjects on days 7, 14, 21, and 27 post-administration to detect humoral immune responses (Figure 21A). Blood was maintained at room temperature for 10 minutes to promote coagulation, and then serum samples were centrifuged at 2000 g for 5 minutes. Serum was collected from the centrifuged samples and stored at -80°C, which was later used for ELISA assays. On day 27 after intranasal administration, bronchoalveolar lavage fluid (BALF), lungs, and spleen were collected from subjects. Serum and other collected biological samples were maintained at -80°C in the presence of protease inhibitors for long-term storage. Splenocytes and pulmonary lymphocytes were dissociated and then frozen in FBS + 10% DMSO and stored in liquid nitrogen vapor phase until further use.

[0144] Example 10: Induction of humoral response using NanoSTING-N composition

[0208] This example demonstrates nucleocapsid-specific IgG and IgA responses induced in subjects by treatment with the NanoSTING-N composition.

[0145]

[0209] Antibody titers against N-protein in serum or other biological fluids were determined using ELISA. Simply put, 1 μg / ml of N-protein (Sinobiological, Pennsylvania, USA) was coated onto ELISA plates (Corning, New York, USA) in PBS overnight at 4°C and 2 hours at 37°C. The plates were then blocked at room temperature for 2 hours in PBS + 1% BSA (Fisher Scientific, Pennsylvania, USA) + 0.1% Tween20 (Sigma-Aldrich, Maryland, USA). After washing, samples were added at different dilutions. The captured antibodies were detected by HRP-conjugated anti-mouse IgG (Jackson ImmunoResearch Laboratories, 1:5,000; Pennsylvania, USA), anti-mouse IgA (Bethil Laboratories, 1:10,000; Texas, USA), and detection antibody against mouse IgA from a mouse total IgA ELISA kit from Invitrogen (California, USA) (1:250). A positive control (anti-NIgG) was obtained from Abeomics (California, USA).

[0146]

[0210] Fourteen days after immunization (D14), 100% of mice treated with NanoSTING-N were seroconverted, and robust anti-NIgG levels with a mean dilution titer of 1:640 were detected (Figure 29). On day 27 after treatment (D27), serum concentrations of anti-NIgG antibodies in serum samples increased, with a mean dilution titer of 1:4,400 detected (Figure 21B). The IgG response at both doses was similar at all time points tested, and the IgG titer induced by NanoSTING-N20 was higher than that induced by NanoSTING-N10, but the difference was not statistically significant (Figure 21B). In contrast to vaccination with trimer NanoSTING-S (first response on day 7), the IgG response was slower, with the response observed only on day 14. SARS-CoV-2-specific antibody responses in bronchoalveolar lavage fluid (BALF) from immunized mice were also evaluated. BALF samples from NanoSTING-N10 and NanoSTING-N20 showed mean IgG titers of 1:15 and 1:86, respectively (Figure 21C).

[0147]

[0211] IgA-mediated protection is an essential component of mucosal immunity against respiratory pathogens. Serum IgA responses were examined. Mice vaccinated with NanoSTING-N10 produced serum IgA levels at an average dilution titer of 1:40, while animals vaccinated with NanoSTING-N20 produced serum IgA levels at an average dilution titer of 1:53 (Figure 21D). Taken together, these results establish that immunization with N-proteins resulted in robust humoral immunity in the serum and lungs.

[0148] Example 11: Processing of spleen and lung for ELISPOT and flow cytometry

[0212] This example illustrates a method for recovering and processing spleen and lung tissue from subjects treated with a NanoSTING composition.

[0149]

[0213] For the isolation of pulmonary lymphocytes, Ca 2+ or Mg 2+ Without injecting into the right ventricle, the pulmonary vascular system was perfused with 1 mM EDTA in 5 ml of PBS. Each lung was cut 100-300 mm using a scalpel. 2The tissue was cut into fragments. The finely chopped tissue was transferred to a test tube containing 5 ml of digestion buffer containing collagenase D (2 mg / ml, Roche, No. 11088858001) and DNase (0.125 mg / ml, Sigma, No. DN25) in 5 ml of RPMI for 1 hour and 30 minutes in a water bath at 37°C, and vortex mixing was performed every 10 minutes. The remaining intact tissue was disintegrated by passing it through a 21 gauge needle (6-8 times). The cells were incubated for 90 minutes and the reaction was stopped by adding 500 μl of ice-cold stop buffer (1 × PBS, 0.1 M EDTA). Tissue fragments and dead cells were removed using a 40 μm disposable cell strainer (Falcon), and the cells were collected after centrifugation. Erythrocytes were lysed by resuspending the cell pellet in 3 ml of ACK lysis buffer (Invitrogen), incubated at room temperature (RT) for 3 minutes, and then centrifuged. The supernatant was discarded, and the cell pellet was resuspended in 5 ml of complete RPMI medium (Corning, New York, USA). Next, the spleen was collected in the RPMI medium and homogenized using the rigid end of a syringe plunger through a 40 μm cell strainer. The splenocytes were then incubated in 3 ml of ACK lysis buffer at room temperature for 3 minutes to remove erythrocytes (RBCs), and then passed through a 40 μm strainer to obtain a single-cell suspension. Pulmonary lymphocytes and splenocytes were counted by the trypan blue exclusion method.

[0150] Example 12: Effect of SARS-CoV-2 nucleocapsid protein on T cell response in vivo

[0214] This example demonstrates the evaluation of the effect of intranasal administration of SARS-CoV-2 nucleocapsid protein on the systemic T cell response.

[0151]

[0215] One of the advantages of administering the N-protein-based compositions disclosed herein (e.g., NanoSTING-N compositions) to subjects is their ability to induce a T-cell response. A Th1 / Tc1 polarization response (e.g., including IFN-γ secretion) may be an indicator of a protective response, while a Th2 polarization response (e.g., including IL-4 secretion) may have the ability to induce antibody-dependent enhancement of infection (ADE) against viral infection. To evaluate the vaccine-induced N-specific T-cell response, splenocytes and pulmonary lymphocytes were harvested 27 days after treatment with SARS-CoV-2 nucleocapsid protein (N-protein) and processed from subjects as described in Example 12.

[0152]

[0216] T cells obtained from the spleen and lung were stimulated with a pool of 15-mer peptides, and antigen-specific T cells were quantified using IFN-γ and IL-4ELISPOT assays. IFN-γ and IL-4ELISPOT assays were performed using the mouse IFN-γELISPOT basic kit (ALP) and the mouse IL-4ELISPOT basic kit. To control cell activation, cultures were treated with 10 ng / ml of 12-myristate phorbol-13-acetate PMA (Sigma, St. Louis, Missouri, USA) and 1 μg / ml of ionomycin (Sigma, St. Louis, Missouri, USA). Complete medium (RPMI supplemented with 10% FBS) was used as a negative control. In vitro, spleen cells and lung lymphocytes (3 × 10⁶ cells) were quantified. 5The cells were stimulated at 37°C for 16-18 hours in pre-coated ELISpot plates (MSIPS4W10 from Millipore) coated with AN18 IFN-γ (1 μg / ml, Mabtech, No. 3321~3-250) and 11B11 IL-4 (1 μg / ml, Mabtech, No. 3311~3-250) coated antibodies with a pool of peptides (Miltenyi Biotec; 130-126-699, Germany) consisting mainly of 15-mer sequences with 11 amino acid overlaps covering the complete sequence of the SARS-coronavirus 2 nucleocapsidrin protein ("N") at a concentration of 1.5 μg / ml / peptide. The following day, the cells were washed and the plates were exposed using biotinylated R4-6A2 anti-IFNγ (Mabtec, numbers 3321-6-250) and BVD6-24G2 anti-IL-4 (Mabtec, numbers 3311-6-250) detection antibodies, respectively. The wells were washed and treated with Extravidin-ALP antibody (Sigma, St. Louis, Missouri, USA) diluted 1:30,000 for 1 hour at room temperature. After washing, the spots were exposed by adding 70 μL / well of BCIP / NBT-Plus substrate (Mabtec, numbers 3650-10) to the wells. The plates were incubated for 20-30 minutes for color development and then washed with water. The spots were quantified using Citation 7 (Biotech Instruments). Each spot corresponds to an individual cytokine-secreting cell. Values ​​are shown as the mean of the three measured sequences minus the background.

[0153]

[0217] Nano-STING-N10 and NanoSTING-N20 immunized mice each had 10 cells. 6 They showed robust and significant splenic T cell responses at an average of 143 and 176 IFN-γ spots per individual (Figure 22, gray and black bars to the left of the dotted line). Animals immunized with NanoSTING-N10 and NanoSTING-N20 showed a robust response. 6An average of 102 and 154 IFN-γ spots per cell showed an elevated T-cell response in the lungs (Figure 22, gray and black bars to the right of the dotted line). In contrast to the IFN-γ (Th1 / Tc1) response, no measurable IL-4 (Th2) response was observed in either splenic or lung cells with treatment with NanoSTING-N10 and NanoSTING-N20 (Figure 22). Taken together, these results establish that intranasal vaccination elicits a strong Th1 response with no evidence of a Th2 response.

[0154] Example 13: Determination of nucleocapsid-specific memory in T cells treated with NanoSTING-N composition.

[0218] This example demonstrates cell surface and intracellular cytokine staining and subsequent flow cytometry analysis of spleen cells and pulmonary lymphocytes from subjects treated with the NanoSTING-N composition.

[0155]

[0219] CD8+ T cell responses can complement antibody-mediated responses and provide protection independently of antibody responses. These experiments investigated the activation and function of N-protein-specific memory CD8+ T cells in the pulmonary airways, lung parenchyma, and spleen. Splenic and pulmonary lymphocytes from animals treated with NanoSTING-N and control were stimulated at 37°C for 16–18 hours with a nucleocapsid protein-peptide pool (Milteny Biotech; 130-126-699, Germany) at a concentration of 1.5 μg / ml / peptide to determine the nucleocapsid protein-specific CD8+ T cell response 18 hours after exposure to the NanoSTING-N composition. Brefelzin A (5 μg / ml, BD Bioscience, no. BD555029) was added during the last 5 hours of incubation. As positive controls, 10 ng / ml PMA (Sigma, St. Louis, Missouri, USA) and 1 μg / ml ionomycin (Sigma, St. Louis, Missouri, USA) were used. Stimulation without nucleocapsid peptides was used as a background control. Cells were collected and stained with Live / Dead Aqua (Thermo Fisher, No. L34965) in PBS, followed by blocking of the Fc receptor with anti-CD16 / CD32 (Thermo Fisher, No. 14-0161-85), and then the following antibody in flow cytometry staining buffer (FACS): anti-CD4 Cells were stained on ice for 30 minutes using AF589 (clone GK1.5; BioLegend, number 100446), anti-CD8b (clone YTS156.7.7; BioLegend, number 126609), anti-CD69 (clone H1.2F3; BioLegend, number 104537), anti-CD137 (clone 1AH2; BD; number 740364), anti-CCR7 (clone 4B12; BioLegend, number 120124), and anti-CD45 (clone 30-F11; BD; number 564279). Cells were washed twice with FACS buffer and then fixed in 100 μl of IC fixation buffer (eBioscience) at room temperature for 30 minutes. Cells were permeabilized for 10 minutes using 200 μl of permeabilization buffer (BD Cytofix lysis kit).Intracellular staining was performed using the antibodies Alexa Fluor488 interferon (IFN) gamma (clone XMG1.2; BD; no. 557735) and granzyme B (clone GB11; BioLegend; no. 515407) overnight at 4°C. Cells were then washed with FACS buffer and analyzed using an LSR-Fortessa flow cytometer (BD Bioscience) with FlowJo® software version 10.8 (Tree Star Inc., Ashland, Oregon, USA) and the flow cytometry gating strategy illustrated in Figure 23. Results were calculated as the total number of cytokine-positive cells minus the background. Antibody concentrations were optimized by titration.

[0156]

[0220] Using the effector molecule granzyme B (GzB) and the activation-inducing marker CD137, N-protein-reactive CD8+ T cells were identified in the spleen and lungs. As described above, ex vivo restimulation with an N-peptide pool resulted in a significant increase in the frequency of activated (CD8+CD137+) and cytotoxic (CD8+GzB+) T cells in both NanoSTING-N10 and NanoSTING-N20 inoculated mice, and to a lesser extent in the lungs (Figure 22). CD137-positive CD8 + The percentage of cells treated with NanoSTING-N10 increased in spleen cells compared to cells treated with the control (see Figures 24A, 24B, 24C, and 24D). GzB-positive CD8 + The percentage of cells also increased in splenic cells treated with NanoSTING-N10 compared to cells treated with the control (see Figures 25A, 25B, 25C, and 25D). CD103, which is normally present in the lungs. + CD69 + CD8 +There was no difference in the overall frequency of T cells between the immunized animals and the control group (see Figures 26A, 26B, 26C, and 26D). Taken together, these results establish a cytotoxic T cell response induced by intranasal immunization in the lungs and spleen.

[0157] Example 14: Induction of an immune response using a NanoSTING composition containing a chimeric spike protein or RSV antigen protein.

[0221] This example illustrates the comprehensive immunity conferred to subjects treated with a NanoSTING composition containing chimeric spike protein antigen (NanoSTING-ChimS) and subjects treated with a NanoSTING composition containing RSV antigen (NanoSTING-RSV).

[0158]

[0222] Recombinant forms of fusion glycoproteins from respiratory syncytial virus B1 containing a C-terminal histidine tag were produced by baculovirus infection of nettle moth (Trichoplusia in) larvae and purified by chromatography.

[0159]

[0223] Serum was collected from subjects treated with (1) NanoSTING composition containing liposomes encapsulating a cGAMP modulator and an alpha mutant spike protein trimer (NanoSTING-ChimS), (2) a beta mutant spike protein trimer, (3) a gamma mutant spike protein trimer ("NanoSTING-varS"), (4) the receptor-binding domain (RBD) portion of the alpha mutant spike protein, or (5) the RBD portion of the gamma mutant spike protein. Samples obtained from subjects 28 days after treatment with each composition of group (1) to (5) showed an increase in antigen-specific IgG titers compared to treatment with animals in the control group immunized with the antigen without adjuvant (Figure 30A). Figure 30B shows ELISA quantification of the reactivity of serum IgA to the alpha variant of the chimeric spike protein trimer, using serum samples obtained 28 days after treatment with the NanoSTING-ChimS composition containing liposomes, alpha variant spike protein trimer antigen, and STING agonist, compared to treatment with the control composition described herein, which contains liposomes lacking the spike protein trimer antigen and STING agonist. IgA titers increased in samples from subjects treated with the NanoSTING-ChimS composition compared to samples from subjects treated with the control.

[0160]

[0224] Figure 31A shows the quantified interferon-gamma (IFNγ) response, measured using the ELISpot assay, in lung samples from subjects treated with the NanoSTING-ChimS composition, which contains different spike protein (S-protein) variants from different peptide pools and represents the entire S-protein-derived peptide pool, compared to treatment with a control composition containing liposomes and lacking chimeric spike protein. Interferon-gamma levels were significantly increased in lung samples from animals treated with NanoSTING compared to samples from animals treated with the control, indicating that the immunostimulatory effect of the NanoSTING composition is robust and generally effective across all antigen variants. Figure 31B shows the quantified interferon-gamma response, measured using the ELISpot assay, in lung samples from subjects treated with the NanoSTING-ChimS composition, which contains liposomes, a gamma-variant chimeric spike protein trimer antigen, and a STING agonist, compared to samples from subjects treated with a control composition containing liposomes and lacking chimeric spike protein. Interferon-gamma levels were significantly increased in lung samples from animals treated with NanoSTING compared to lung samples from animals treated with the control, illustrating that the effect of the NanoSTING composition on the target immune response is specific to individual antigen variants.

[0161]

[0225] Figures 32A and 32B show the reactivity of IgG to the B1 strain respiratory syncytial virus F protein (RSV-F) in ELISA assays performed on serum obtained at days 7 and 14, respectively, after treatment with the composition described herein, which contains liposomes, an RSV-F-derived antigen, and a STING agonist ("NanoSTING-RSV"), compared to treatment with the control composition described herein, which contains liposomes and lacks a chimeric spike protein. RSV antigen-specific IgG levels increased at both days 7 and 14 compared to samples from animals treated with the control, indicating that comprehensive immunity was conferred to the subjects after treatment with the NanoSTING composition containing the antigen.

[0162] Example 15. Stability of compositions containing lipid nanoparticles and / or modulator proteins.

[0226] This example demonstrates the observation of the stability of the compositions described herein, including modulator proteins and lipid nanoparticles, or the modulator protein alone.

[0163]

[0227] Modulator proteins (e.g., pattern recognition receptor agonist proteins, e.g., STING agonists) may be lyophilized for storage. Lyophilized modulator proteins (e.g., pattern recognition receptor agonist proteins, e.g., STING agonists as described herein) retain their efficacy (e.g., after rehydration) in the compositions and methods described herein for at least 11 months when stored at 4°C. Lyophilized lipid-based nanoparticle compositions as described herein (e.g., those described in Example 1) also retain their efficacy (e.g., after rehydration) in the compositions and methods described herein. In many applications, lyophilized compositions or their components are reconstituted in a sterile solution before use (e.g., hydrated). In some cases, lyophilized compositions or their components are reconstituted in a sterile solution containing one or more excipients (e.g., pharmaceutically acceptable excipients).

[0164]

[0228] In some embodiments, the NanoSTING composition is formulated by mixing a modulator protein with lipid-based nanoparticles (for example, after rehydration if the components are lyophilized). In some embodiments, the NanoSTING composition, which contains a modulator protein and lipid-based nanoparticles but does not contain an antigen protein (e.g., an N-protein or S-protein), is stable for at least 11 months when formulated in suspension and stored at 4°C.

[0165] Example 16. Prophylactic treatment for respiratory viral infections in mammals using NanoSTING composition.

[0229] This example demonstrates a reduction in viral load in mammalian subjects prophylactically treated with a composition described herein comprising a STING agonist encapsulated in nanoparticles.

[0166]

[0230] The nasal cavities of hamsters were treated with a NanoSTING composition containing a cGAMP STING agonist (modulator) encapsulated in nanoparticles containing DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a 10:1:1:1 ratio for 24 hours (1 day) and 6 hours, respectively, before infection with a 10,000 TCID50 B.1.1.7 (alpha variant) virus load (Figure 37A). The NanoSTING composition was administered as a monotherapy treatment, and the NanoSTING composition lacked antigenic components.

[0167]

[0231] As shown in Figure 37B, body weight was measured daily from loading to 5 days post-loading for subjects who were not subjected to viral loading (circles), subjects who received a pseudo-phosphate-buffered saline (PBS) loading, subjects who received a NanoSTING composition containing 30 μg (30 μg) of nanoparticles encapsulated with a STING agonist modulator at each dosing time point, and subjects who received a NanoSTING composition containing 120 μg (120 μg) of nanoparticles and a STING agonist modulator encapsulated within them at each dosing time point. It was found that the body weight of subjects receiving the NanoSTING composition (30 μg or 120 μg dose) was not significantly different from that of subjects who were not subjected to viral loading. Subjects receiving the NanoSTING composition (30 μg or 120 μg dose) had significantly heavier body weight on days 4 and 5 compared to subjects who received viral loading and PBS treatment. Similarly, subjects receiving the 30 μg dose of the NanoSTING composition had significantly heavier body weight than subjects who received viral loading and PBS treatment on day 3.

[0168]

[0232] The fact that hamster subjects maintained their body weight during viral loading after pretreatment with the NanoSTING composition strongly suggests that similar results may be achieved in human subjects. These data represent best-in-class results in preventing weight loss in a hamster coronavirus loading model of prophylactic treatment.

[0169]

[0233] TCID50 levels were also measured in lung tissue (BALT, Figure 37C) and nasal tissue (NALT, Figure 37D) and quantified on day 2. The results, as shown in Figure 37C, show that the infectious viral load in lung tissue (quantified as 50% tissue culture infectious dose ("TCID50 / mg")) was significantly reduced in subjects treated with either 30 μg of NanoSTING composition (p=0.05) or 120 μg of NanoSTING composition (p=0.02) compared to subjects treated with PBS after receiving a viral load. The results also show, as shown in Figure 37D, that the infectious viral load in nasal tissue was also significantly reduced in subjects treated with either 30 μg of NanoSTING composition (p=0.03) or 120 μg of NanoSTING composition (p=0.03) compared to subjects treated with PBS after receiving a viral load.

[0170] Example 17. Multiple administrations of NanoSTING composition

[0234] This example demonstrates that repeated treatment with the NanoSTING composition described herein is well acceptable depending on the subject.

[0171]

[0235] The nasal cavities of hamsters were treated once daily for four consecutive days with a NanoSTING composition containing a cGAMP STING agonist (modulator) encapsulated in nanoparticles containing DPPC, DPPG, cholesterol, and DPPE-PEG2000 in a ratio of 10:1:1:1 (Figure 38A). The NanoSTING composition was administered as a monotherapy treatment (60 μg of NanoSTING composition per day), and the NanoSTING composition lacked the antigenic component.

[0172]

[0236] As shown in Figure 37B, the body temperature of the subjects was not significantly different from that of subjects who did not receive the NanoSTING composition on any of the following days: day 1, day 2, day 3, or day 4 after the initial administration of the NanoSTING composition. As shown in Figure 38C, the body weight (square data points) of subjects receiving the NanoSTING composition was not significantly different from that of control subjects who did not receive the NanoSTING composition (circular data points). These results indicate that the hamster subjects tolerated repeated treatment with the NanoSTING composition well, and that similar results should be obtained in human subjects.

[0173] Example 18. Activation of interferon-stimulated genes with NanoSTING composition

[0237] This example demonstrates that treatment with the NanoSTING composition activates interferon-stimulated genes in vivo.

[0174]

[0238] THP-1 dual cells were cultured with NanoSTING compositions containing a cGAMP STING agonist (modulator) encapsulated in nanoparticles containing DPPC, DPPG, cholesterol, and DPPE-PEG2000 in 10:1:1:1 ratios, respectively, in 10 μg, 5 μg, or 2.5 μg doses. Interferon-stimulated gene activation was quantified by measuring luminescence (relative luminescence units, RLU) in the cells (Figure 39A). The NanoSTING compositions were administered as monotherapy treatments, and the NanoSTING compositions lacked antigenic components. After 24 hours, luminescence values ​​greater than 95,000 RLU were observed in THP-1 cells receiving 10 μg of NanoSTING composition, greater than 85,000 RLU in THP-1 cells receiving 5 μg of NanoSTING composition, and less than 50,000 RLU in THP-1 cells receiving 2.5 μg of NanoSTING composition. In all NanoSTING-treated THP-1 cell groups, <50 RLU luminescence was recorded at the time of application of the NanoSTING composition to the cells (zero time point). Cells not treated with the NanoSTING composition showed <50 RLU luminescence 24 hours after dummy treatment. As shown in Figure 39B, THP-1 cells treated with the positive control vector (poly(dA:dT) / LyoVec® vector) showed less than 5,000 RLU at 6 and 12 hours after application of the positive control vector, and less than 40,000 RLU at 24 hours after application of the positive control vector.

[0175]

[0239] These results demonstrate that the NanoSTING composition activates interferon-stimulated genes in vitro at concentrations of 5 μg and 10 μg. Embodiment

[0240] In some embodiments, the compositions or methods disclosed herein may include a nucleocapsid protein (N-protein) or a fragment thereof and / or a spike protein (S-protein) or a fragment thereof. In some cases, the N-protein or fragment thereof described herein may be based on the alpha strain of the SARS-CoV-2 nucleocapsid protein. In some cases, the S-protein or fragment thereof described herein may be based on the beta strain of the SARS-CoV-2 spike protein.

[0176]

[0241] In some cases, an N-protein may have an amino acid sequence identical to all or part of Sequence ID No. 1 (e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100%), where Sequence ID No. 1 is as follows (using single-letter abbreviations for amino acids, e.g., similar to the amino acid codes used by the International Union of Pure and Applied Chemistry (IUPAC) and the International Nucleotide Sequence Database): mslngpqnqrnapritfggpsdstgsnqngersgarskqrrpqglpnntaswftaltqhgkedlkfprgqgvpintnsspddqigyyrratrrirggdgkmkdl sprwyfyylgtgpeaglpygankdgiiwvategalntpkdhigtrnpannaaivlqlpqgttlpkgfyaegsrggsqassrsssrsrnssrnstpgsskrtspar magnggdaalalllldrlnqleskmfgkgqqqqgqtvtkksaaeaskkprqkrtatkaynvtqafgrrgpeqtqgnfgdqelirqgtdykhwpqiaqfapsasaf fgmsrigmevtpsgtwltytgaiklddkdpnfkdqvillnkhidayktfpptepkkdkkkkadetqalpqrqkkqqtvtllpaadlddfskqlqqsmssadstqa

[0242] In some cases, the N-protein may be encoded by a nucleotide sequence identical to all or part of SEQ ID NO: 2 (e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100%) (e.g., in oligonucleotides or vectors, e.g., in bacterial cells, mammalian cells, or plasmids), where SEQ ID NO: 2 is as follows (using a four-letter nucleotide code, e.g., adenine (A), cytosine (C), thymine (T), and guanine (T)):

[0243] In some cases, the S-protein may have an amino acid sequence identical to all or part of Sequence ID No. 3 (for example, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100%), and Sequence ID No. 3 is as follows (using single-letter abbreviations for amino acids):

[0244] In some cases, the S-protein may be encoded by a nucleotide sequence identical to all or part of SEQ ID NO: 4 (e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100%) (e.g., in an oligonucleotide or vector, e.g., in a bacterial cell or plasmid), where SEQ ID NO: 4 is as follows (using a four-letter nucleotide code, e.g., adenine (A), cytosine (C), thymine (T), and guanine (T)):

[0245] Unless otherwise specified, all technical terms used herein have the same meaning as those generally understood by those skilled in the art of the subject matter. It will be understood that both the general descriptions above and the detailed descriptions below are illustrative and explanatory, and do not limit the claimed subject matter.

[0177]

[0246] Chapter headings used herein are for systematizing purposes only and should not be construed as limiting the subject matter described herein. All documents or parts of documents cited herein, but not limited to, patents, patent applications, articles, books, and professional works, in whole, are expressly incorporated herein by reference for any purpose. If one or more of the incorporated documents and similar materials define terms in a manner that conflicts with the definitions of terms given herein, this application shall prevail.

[0178]

[0247] The singular forms “a,” “an,” and “the,” as used herein, are intended to also include the plural forms unless the context clearly indicates otherwise. For example, unless otherwise specified, the words “a” or “an” mean “at least one,” and the use of “or” means “and / or.” The term “and / or,” as used herein, includes any combination of one or more of the related items listed. The terms “contain” and / or “contain,” or “have” and / or “have,” as used herein, identify the presence of the described features, regions, integers, processes, operations, elements, and / or components, but do not exclude the presence of one or more additional features, regions, integers, processes, operations, elements, components, and / or groups thereof. Furthermore, unless otherwise specified, terms such as "element" or "component" encompass both elements or components containing one unit and elements or components containing more than one unit.

[0179]

[0248] Where used herein, A and / or B encompass one or more of A or B, and combinations thereof, for example, A and B. While terms such as “first,” “second,” “third,” etc., may be used herein to describe various elements, components, areas, and / or sections, it will be understood that these elements, components, areas, and / or sections are not necessarily limited by these terms. These terms may simply be used to distinguish one element, component, area, or section from another. Thus, a first element, component, area, or section discussed herein may, in some cases, be referred to as a second element, component, area, or section without departing from the teachings of the disclosure of the present invention.

[0180]

[0249] The term "subjects," as used herein, includes mammals. Mammals include rats, mice, non-human primates, and primates such as humans.

[0250] Throughout this disclosure, various embodiments are presented in the form of scope. It should be understood that the scope descriptions are for convenience and brevity only and should not be interpreted as inflexible limitations on the scope of any embodiment. Accordingly, unless otherwise clearly indicated in the context, the scope descriptions should be considered to include all specifically disclosed possible subranges, plus individual numerical values ​​within that range up to one-tenth of the lower limit unit. For example, a scope description such as 1-6 should be considered to have the specifically disclosed subranges, e.g., 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, etc., plus individual values ​​within that range, e.g., 1.1, 2, 2.3, 5, and 5.9. This applies regardless of the width of the range. Upper and lower limits of the range between these can independently be included in smaller ranges, which are also encompassed in the invention, although there may be limitations that are specifically excluded within the stated range. If the stated range includes one or both of the limit values, the range excluding one or both of those included limit values ​​is also included in the invention, unless the context clearly indicates otherwise.

[0181]

[0251] As used herein and in the claims, unless otherwise specified, the terms “about,” “approximately,” or “substantially” mean variations of ±0.1%, ±1%, ±2%, ±3%, ±4%, ±5%, ±6%, ±7%, ±8%, ±9%, ±10%, ±11%, ±12%, ±14%, ±15%, or ±20%, including numerical increases, depending on the embodiment. As a non-limiting example, about 100 nanometers (nm) means, depending on the embodiment, a range of 95 to 105 nanometers (which is ±5% of 100 nanometers), a range of 90 to 110 nanometers (which is ±10% of 100 nanometers), or a range of 85 to 115 nanometers (which is ±15% of 100 nanometers).

[0182]

[0252] While specific embodiments and examples are provided in the foregoing description, the subject matter of the invention extends beyond the specifically disclosed embodiments to other alternative embodiments and / or uses, and even to their substitutes and equivalents. In any method or process disclosed herein, the operation or behavior of the method or process may be performed in any preferred order and is not necessarily limited to any particular disclosed order. Various operations may be described sequentially as multiple separate operations in a manner that may be useful in understanding a particular embodiment, but the order of description should not necessarily be interpreted as meaning that these operations are order-dependent. In addition, the structures, systems, and / or devices described herein may be embodied as integrated separate components or as separate components.

[0183]

[0253] For the purpose of comparing various embodiments, specific forms and the advantages of these embodiments are described. Not all such forms or advantages are necessarily achieved by any particular embodiment. Therefore, for example, various embodiments may be made in a manner that achieves or optimizes one or more advantages or groups of advantages as taught herein, and other forms or advantages that may be taught or suggested herein are not necessarily achieved.

[0184]

[0254] Preferred embodiments of the present invention have been shown and described herein, but it will be apparent to those skilled in the art that such embodiments are provided merely as examples. Those skilled in the art will anticipate numerous variations, modifications, and substitutions without departing from the invention. It will be understood that various alternatives to the embodiments of the invention described herein can be employed in the practice of the invention. The following claims are intended to define the scope of the invention and to encompass the methods and structures within these claims and their equivalents.

Claims

1. A composition comprising an antigen and a lipid-based particle, wherein the lipid-based particle comprises a modulator that activates or inhibits the stimulator of interferon genes (STING) pathway and the antigen is a nucleocapsid protein or a portion thereof, or A polynucleotide encoding a nucleocapsid protein or a portion thereof; The composition as described above, which is or comprises:

2. The composition of claim 1, wherein the antigen is or comprises a SARS-CoV2 nucleocapsid protein or a portion thereof, wherein the antigen may be a monomeric or multimeric form of the SARS-CoV2 nucleocapsid protein, and wherein the SARS-CoV2 nucleocapsid protein comprises an A220V mutation.

3. The antigen is Spike protein or a portion thereof, or A polynucleotide expressing the spike protein or a portion thereof; wherein the antigen may comprise a SARS-CoV2 spike protein, and the antigen may comprise a mixture of SARS-CoV2 spike proteins comprising different mutations.

4. The SARS-CoV2 spike protein, A monomeric form of the SARS-CoV2 spike protein, A monomeric form of the receptor binding domain (RBD) of the SARS-CoV2 spike protein; Multimeric forms of the SARS-CoV2 spike protein; Multimeric forms of the receptor binding domain of the SARS-CoV2 spike protein; The dimeric form of the SARS-CoV2 spike protein, A dimeric form of the receptor binding domain of the SARS-CoV2 spike protein; The trimeric form of the SARS-CoV2 spike protein, a trimeric form of the receptor binding domain of the SARS-CoV2 spike protein, or Combinations of these The composition of claim 3 , 5. The composition of claim 3, wherein the SARS-CoV2 spike protein is a chimeric spike protein and / or comprises the following mutations: D614G, A222V, S477N, D80Y, S98F or any combination thereof.

6. (1) The antigen is associated with the surface of the lipid-based particle. (2) at least a portion of the antigen is integrated into the membrane of the lipid-based particle; or (3) The composition according to any one of claims 1 to 5, wherein at least a portion of the antigen is encapsulated within the lipid-based particle.

7. A composition described in any one of claims 1 to 6, containing 0.1 μg to 200 μg of the antigen.

8. A composition described in any one of claims 1 to 7, administered to prevent or treat a disease.

9. A composition described in any of claims 1 to 8, administered to a first subject to prevent transmission of a disease in the first subject to a second subject.

10. The composition according to any one of claims 8 to 9, wherein the disease is caused by a pathogen.

11. The composition of any of claims 8 to 10, wherein the disease is an infectious disease caused by a coronavirus, wherein the coronavirus may be SARS-CoV, SARSr-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, MERS-CoV, SARS-CoV2, a mutant strain of SARS-CoV2, or a combination thereof.

12. The composition of claim 8, wherein the composition is administered to elicit an immune response against a disease, (1) Innate immune responses include activation of interferon regulatory factors (IRFs), (2) the innate immune response is activation of nuclear factor-κB (NF-κB), or (3) the innate immune response is characterized by the synthesis and secretion of type I and type III interferons and the subsequent upregulation of IFN-stimulated genes (ISGs); The composition may provide:

13. A composition administered to prevent or treat a disease or condition in a subject, comprising: The composition comprises a lipid-based particle, wherein the lipid-based particle comprises a modulator that activates or inhibits the stimulator of interferon genes (STING) pathway; The above composition, wherein the composition does not contain an antigen and / or the composition is not administered to the subject together with an antigen.

14. The composition described in claim 13, wherein the disease or condition is an infectious disease caused by a pathogen.

15. 1. A composition for administration to a subject to prevent or treat an infection caused by a pathogen, comprising: The composition comprises a lipid-based particle, wherein the lipid-based particle comprises a modulator that activates or inhibits the stimulator of interferon genes (STING) pathway; The composition comprises the following antigens (1) to (4): (1) an antigen that elicits an immune response against a pathogen; (2) An antigen that elicits a humoral or T cell immune response against a pathogen; (3) an antigen comprising a peptide or protein associated with a pathogen, or a portion thereof; (4) an antigen comprising a polynucleotide encoding a peptide or protein associated with a pathogen, or a portion thereof; and / or the composition is not administered to a subject together with any of the antigens (1) to (4) above.

16. The composition according to any one of claims 13 to 15, for use in preventing the transmission of a disease to another subject.

17. A composition described in any of claims 13 to 16, wherein the subject has not received an antigen that elicits an immune response against a disease or condition, and is not in the process of receiving an antigen that elicits an immune response against a disease or condition.

18. The composition of any one of claims 13 to 17, administered as a monotherapy.

19. The composition of any of claims 14 to 18, wherein the pathogen is selected from influenza viruses such as influenza A virus and influenza B virus, parainfluenza viruses, adenoviruses, enteroviruses, coronaviruses, respiratory syncytial viruses, rhinoviruses, DNA viruses, RNA viruses, or combinations thereof.

20. The composition of claim 19, wherein the pathogen is a coronavirus selected from the group consisting of severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome-related coronavirus (SARSr-CoV), human coronavirus 229E (HCoV-229E), human coronavirus NL63 (HCoV-NL63), human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), Middle East respiratory syndrome-related coronavirus (MERS-CoV), severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), a mutant of SARS-CoV-2, and combinations thereof.

21. The composition described in claim 13, 17 or 18, wherein the disease or condition is cancer.

22. The composition of any one of claims 1 to 21, wherein the modulator is an agonist of the STING pathway.

23. The composition of any of claims 1 to 22, wherein the modulator is bis-(3',5')-cyclic dimeric guanosine monophosphate (c-di-GMP), cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), amidobenzimidazole, an amidobenzimidazole derivative, a nucleotide modulator, a plasmid DNA modulator, a nucleic acid modulator or a combination thereof, preferably wherein the modulator is cGAMP.

24. 24. The composition of any of claims 1 to 23, wherein the composition comprises at least 3 μg, at least 30 μg or at least 120 μg of the modulator.

25. The method of claim 1, wherein the lipid-based particle is a liposome. (2) the lipid-based particles are anionic; (3) The lipid-based particles have an average hydrodynamic particle size of less than 300 nm and / or a polydispersity index of less than 0.25; or (4) The lipid-based particle comprises an anionic lipid. The composition according to any one of claims 1 to 24.

26. 26. The composition of any of claims 1-25, wherein the lipid-based particle comprises DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DPPG (1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)), DPPE-PEG2000 (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]), cholesterol, or a combination thereof.

27. 27. The composition of claim 26, wherein the lipid-based particle comprises DPPC, DPPG, cholesterol and DPPE-PEG2000 in a ratio of approximately 10:1:1:

1.

28. A composition described in any one of claims 1 to 27, wherein the modulator is encapsulated within a lipid-based particle.

29. A composition described in any one of claims 1 to 28, which is a therapeutic composition.

30. 30. The composition of any of claims 1 to 29, wherein the composition is administered to a subject intravenously, intramuscularly, intradermally, intraperitoneally, subcutaneously, spray-based, aerosol-based, in ovo, orally, intraocularly, intratracheally, intranasally, by inhalation, or a combination thereof, preferably administered intranasally or by inhalation.

31. The composition of any of claims 1 to 30, wherein the composition is administered in a single dose or in multiple doses.

32. A composition described in any of claims 1 to 31, wherein the composition is administered to a subject before or after the subject is exposed to a pathogen.